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Abstract 
Advances in neuroimaging and biomarkers now provide the ability to detect evidence for 
the pathophysiological process of Alzheimer’s disease (AD) before clinically detectable 
dementia. Because of these findings, AD research has begun to focus on the preclinical 
or prodromal stages of the disease. For example, many clinical trials and laboratory-
based studied have examined the clinical benefit of earlier AD intervention, such as pre-
symptomatic stages of AD, based on the belief that it is more likely to achieve disease 
modification. The economic evaluation of potential interventions on AD, which mainly 
extends to include the earlier disease stages by using biomarker testing to predict the 
risk of disease progression, needs to be updated. Accordingly, the overall objective of 
this thesis is to quantify the value of using cerebrospinal fluid (CSF) biomarker testing for 
early-targeted treatment on patients with mild cognitive impairment who are at risk of 
developing AD. Firstly, I examined whether CSF biomarker testing can categorize MCI 
patients into different risk groups of developing AD, and thus allowing for targeted early 
treatment on MCI patients. Secondly, I conducted a cost-effectiveness analysis to 
evaluate the different treatment strategies with or without testing information involved by 
developing a decision model to synthesize all relevant evidence and project the 
expected value of outcomes of interest for each proposed alternative. Finally, I further 
address key challenges based on the current evidence by estimating the societal value 
of reducing uncertainty surrounding the decision model through further research. 
Economic evidence about the relative costs and outcomes of health and social care can 
assist decision makers in determining the best use of scarce healthcare resources.  
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2 
1.1 Alzheimer’s disease 
1.1.1 Definition and diagnosis 
Alzheimer’s disease (AD), the most common type of dementia, is a devastating 
neurodegenerative disease that impairs memory, thought, and behavior; reduces quality 
of life; and decreases survival. It is the most common cause of dementia, accounting for 
60 to 80 percent of all dementia cases.1 No single test can prove a person has AD. A 
clinical diagnosis is made though several assessments, including a medical history, a 
mental status evaluation, a physical and neurological examination and laboratory tests, 
that consider all possible causes.2 Dementia is incorporated into the diagnostic 
categories of major and mild neurocognitive disorders in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) in 2013.3 For both major and mild neurocognitive 
disorders, DSM-5 instructs physicians to specify whether the condition is due to AD or 
other causes.1 The criteria established by the National Institute of Neurological and 
Communicative Diseases and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) for a diagnosis of probable AD (i.e., no other 
cause for the symptoms can be found) include: 1) dementia established by examination 
and objective testing; 2) deficits in two or more cognitive areas; 3) progressive 
worsening of memory and other cognitive functions; 4) no disturbance in consciousness; 
and 5) onset between ages 40 and 90. Recently, the NINCDS-ADRDA also defined 
three stages of AD - the preclinical, the prodromal and the dementia stages, which 
allows AD to be diagnosed before the onset of clinical symptoms, such as memory loss. 
In addition, they recommend the use of biomarker tests to assist in the diagnosis of the 
presence of disease.1 However, more research is needed before this proposed 
operational research criteria and guidelines could be used in clinical settings.1,4  
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1.1.2 Burden of disease 
An estimated 5.2 million people in the US had AD dementia in 2014, and it is now the 
sixth leading cause of death.1 As age is the biggest risk factor for the disease, with the 
aging of the population, the disease burden in the US will increase to an estimated 7.7 
million cases in 2030 and 11 to 16 million cases in 2050.5 These numbers do not include 
the large number of people with mild cognitive impairment (MCI), a significant proportion 
of whom will progress to AD. Patients with AD are high users of health care and long-
term care services. In the US, there are more than 15 million family caregivers who 
provide unpaid care for people with AD and other dementia are under great emotional 
burden.1 AD and other types of dementia cost Medicare $113 billion per year and 
Medicaid $37 billion per year. The total annual direct costs of AD are estimated at $214 
billion.1  
AD places considerable and increasing burden on patients, caregivers and 
society, as more people live long enough to become at-risk. As their independence 
continues to decline, AD patients place an increasing physical, psychological, and 
financial burden on family caregivers. As a result, they are frequently placed in 
residential care/assisted living facilities, nursing homes, or geropsychiatric hospitals. 
 
1.1.3 Phases of AD 
Based on clinical experience and analysis of cognitive testing, the clinical disease stages 
of AD can be divided into three phases in a recent workshop.6 The first phase is a 
preclinical phase7 in which individuals are cognitively normal, but have some AD 
pathological changes.7 To some extent, labeling these individuals as having pre-
symptomatic AD is hypothetical, because some of these individuals will die from other 
causes without ever expressing clinical symptoms.8-10 The assertion is that an 
asymptomatic individual with pathological changes that are indicative of AD has a higher 
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risk of becoming symptomatic if he or she lived long enough compared with those 
without any changes. The second phase is a prodromal phase of AD,4 commonly 
referred to as MCI,11 and it is characterized by the onset of the earliest cognitive 
symptoms (typically deficits in episodic memory) that do not meet the criteria for 
dementia. The severity of cognitive impairment in the MCI phase of AD varies from the 
earliest appearance of memory dysfunction to more widespread dysfunction in other 
cognitive domains. This prodromal phase has recently taken on critical importance 
because of the potential it offers to treat and potentially delay the AD process at the 
point of its earliest manifestation. The final phase in the evolution of AD is dementia,12 
defined as impairments in multiple domains that are severe enough to produce loss of 
function. During this phase, the important clinical considerations are level of dementia 
severity and the rate of its progression. Pre-dementia phases of AD, including the 
preclinical and prodromal phases mentioned above, may serve as an opportunity for 
early detection with potential to delay the progression of AD. Many researchers in the 
field believe that future treatments to slow or stop the progression of AD will be most 
effective when administered during the preclinical and MCI stages of the disease.1  
 
1.1.4 Assessments of AD 
AD is heterogeneous in its presentation and disease course across the main symptom 
domains of cognition, function, and behavior. Several instruments are commonly used to 
assess the severity of AD. The Clinical Dementia Rating scale (CDR)13,14 combines both 
cognitive and functional domains to determine the stage of AD patients. CDR is a five-
point scale, which quantifies dementia severity from very mild (CDR-0.5) to mild (CDR-
1), moderate (CDR-2), and severe (CDR-3) in addition to no cognitive impairment (CDR-
0).15 The Mini-Mental State Examination (MMSE)16 is a 30-item screening tool for the 
assessment of cognitive impairment and also a common tool for determining the severity 
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of AD. The cut-offs used to define severity levels are not consistent across studies,17 but 
in general scores between 21 to 24 are considered mild, 10 to 20 moderate, and ≤ 9 
points severe.18 The scale of AD and associated disorders (ADAS) was designed to 
measure the severity of the most important symptoms of AD.19 Its subscale ADAS-cog 
(total 70 points, with higher scores (≥ 18) indicating greater cognitive impairment) 
consists of 11 tasks measuring the disturbances of memory, language, praxis, attention 
and other cognitive abilities and is commonly used to estimate the treatment efficacy in 
the clinical trials. A four-point change on the ADAS-Cog at 6 months is considered as 
indicating a clinically important difference.20,21 The Global Deterioration Scale (GDS),22 
which divided AD into 7 stage of ability, is based on implicit assumptions about the 
linearity, temporality, and interdependence of cognitive, functional, and behavioral 
impairment in the disease. The Allen Cognitive Levels (ACL) Assessment is an 
occupational therapy tool designed to characterize an individual's level of cognitive and 
adaptive functioning,23,24 which informs the level of assistance a person is likely to need 
in order to perform routine tasks (6 levels ranging from coma [0.8] to normal [6.0]), and 
how that person will perform in novel situations.  
 
1.1.5 Currently available treatments for AD patients 
The current standard of care for patients with mild to moderate AD includes treatment 
with cholinesterase inhibitors (ChEIs), including tacrine, donepezil, galantamine, or 
rivastigmine, to improve cognitive function,25 and it can be started as soon as dementia 
is diagnosed.26 Results of 10 randomized, double blind, placebo controlled trials (RCTs) 
demonstrated that treatment for 6 months with ChEIs at the recommended dose for 
people with dementia due to AD produced improvements in cognitive function, on 
average -2.7 points (95%CI: -3.0 to -2.3), in the midrange of the 70 point ADAS-Cog 
scale.27 A few studies have also shown that ChEI treatment of AD patients reduces the 
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time required for family care, or delays the time until nursing home institutionalization 
becomes necessary.28-30 For example, in a 30-week RCT with an open-label extension, 
patients with mild to moderate AD who remained on tacrine and were receiving doses < 
80 mg/d or < 120 mg/d were more likely to have entered a nursing home than patients 
on higher doses (odds ratios= 2.7 [95% CI: 1.4-5.2] or 2.8 [95% CI: 1.5-5.2], 
respectively).31 Wattmo et al.29 found that a higher mean dose of ChEIs postponed 
institutionalization in AD patients (hazard ratio= 0.63, 95%CI: 0.47–0.85). Furthermore, 
Lopez et al.30 showed in a comparison between treated and untreated matched AD 
cohorts that ChEI use was associated with a protective effect on nursing home 
admission (relative risk [RR]= 0.095, 95% CI: 0.03-0.30). On the other hand, in a 12-
week RCT of donepezil treatment on patients with mild to moderate AD,32 results 
indicated the RR of entering institutional care in the donepezil group compared with 
placebo was 0.97 but not statistically significant (95% CI: 0.72-1.30). This is similar to 
what Gaugler et al. found in a systematic review, which concluded that studies of ChEI 
treatment in AD patients, with nursing home placement as an outcome measure, were 
inconclusive.33 In general, The N-methyl-d-aspartate (NMDA) antagonist memantine has 
also been shown to improve cognitive function (language, memory, and praxis) in 
patients with moderate to severe AD (MMSE < 20) compared to placebo-treated patients 
in a post-hoc anlaysis.34 In addition, the common non-cognitive neuropsychiatric 
symptoms of AD (such as mood disorder, agitation and psychosis) are often treated with 
prescribed medication, even though no existing drug is specifically indicated for their 
management.35 To date, there is no treatment with a proven disease-modifying effect on 
underlying disease pathology of AD. While current guidelines support the use of ChEIs 
in patients with mild to moderate AD,36 results from more recent clinical trials37,38 
speculates that ChEI treatment may also be effective across all stages of AD, as well as 
for MCI.39 
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1.2 Mild cognitive impairment 
1.2.1 Definition of diagnosis 
MCI is a condition in which a person has problems with memory, language or another 
essential cognitive function that are noticeable to others and show up on cognitive tests, 
but are not severe enough to interfere with daily life.40 The diagnosis for amnestic MCI 
(aMCI) is usually established using the Petersen criteria,41 revised Petersen criteria 
(aMCI, Table 1.1),42,43 CDR equal to 0.5,13,15 or an MMSE score between 24 and 30.44 
The differentiation of dementia from MCI in general rests on the determination of 
whether or not there is significant interference in the ability to function at work or in usual 
daily activities.12 
 
Table 1.1 Petersen’s criteria for amnestic mild cognitive impairment.11,42 
Memory complaint usually corroborated by an informant 
Objective memory impairment for age 
Essentially preserved general cognitive function 
Largely intact functional activities 
Not demented 
 
 
1.2.2 Subtypes of MCI 
The term MCI was first used to refer to an early stage of AD dementia (i.e., aMCI). It was 
in widespread use after the introduction of the Petersen criteria43 for aMCI, which 
subsequently became a subtype of a broader concept of MCI, as defined by an 
International Working Group (IWG)45 to cover causes including but not limited to AD. 
Most studies today subtype MCI into aMCI and non-amnestic MCI (naMCI) depending 
on whether or not memory is impaired,46 or further into single or multiple cognitive 
domains without requiring memory deficits.11,42,47 MCI subtypes were developed with the 
expectation that aMCI was likely to be a transitional state between normal cognition and 
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AD, whereas naMCI may progress to non-AD dementia,47 which is most likely to be 
vascular dementia in the elderly population.46 In clinical trials involving patients with 
aMCI, more than 90% of those with progression to dementia had clinical signs of AD.37,48  
 
1.2.3 Epidemiology of MCI 
About 10-20 percent of people aged 65 and older have MCI.49-51 The incidence rates of 
MCI varied widely. A meta-analysis with nine studies indicated that the incidence of 
developing MCI among the general population ranged between 9.9 and 40.6 per 1,000 
person-years,52 and incidence rate from the Aging, Demographics, and Memory Study 
was even higher (60.4 per 1,000 person-years).53 These variations might be affected by 
differences in the study characteristics, such as age, sex, or disease history, or in the 
diagnostic criteria used for MCI and their operational definition.52,54   
MCI patients are at increased risk of developing AD, with an annual rate of 
conversion to AD of 3-10 percent in community-based populations and 10-15 percent in 
specialty clinics in terms of different follow-up periods of studies.42,43,48,55-57 The higher 
rates in the specialty setting may reflect the fact that cognitive impairment is typically 
more advanced by the time a person seeks medical attention, the heterogeneity of study 
subjects, or from the discrepancies in the definition of MCI in each study.48,52  
 
1.2.4 Use of biomarker testing to predict the progression from MCI to AD   
AD-specific biomarkers are compounds obtained from bodily fluids or tissue, such as 
cerebrospinal fluid (CSF) assays, or technically derived correlates of AD pathology, such 
as brain imaging markers. Four neuroimaging modalities have been used to provide 
evidence for the presence of AD: structural magnetic resonance imaging (MRI), 
functional MRI (fMRI), magnetic resonance spectroscopy (MRS) and positron emission 
tomography (PET).58 In addition, four CSF biomarkers have been shown to directly 
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reflect brain neurochemistry: Aβ40, Aβ1-42, total tau (T-au) and phosphorylated tau (P-
tau).58 Findings from these tests may identify MCI patients who are at risk for more rapid 
progression to dementia.59 Two categories of biomarkers have been extensively studied 
for their ability to discriminate between AD patients and cognitively normal controls: 1) 
Aβ (β-amyloid), including CSF Aβ1-42 or PET amyloid imaging, and 2) biomarkers of 
neuronal injury, including CSF T-tau or P-tau, hippocampal, or medial temporal lobe 
atrophy on MRI, and temporoparietal/precuneus hypometabolism or hypoperfusion on 
PET or single-photon emission computed tomography (SPECT).60  
According to the diagnostic guidelines of AD updated during the recent NIA-AA 
workshop,4 test results that include information from these two biomarker categories 
could be used as a conceptual criteria to assess the likelihood that MCI symptoms are 
due to the underlying pathophysiology of AD.48 When biomarkers in both Aβ and 
neuronal injury categories are positive, there is high likelihood that MCI symptoms are 
due to AD. In other words, these biomarkers reflect the AD pathophysiological process in 
an individual with MCI, which implies that detection of MCI patients with positive 
biomarkers can predict a higher rate of cognitive and functional progression to AD as 
compared with MCI patients whose biomarkers are defined as negative.60 Given the 
current lack of standardization among the techniques and the lack of agreement on cut-
off thresholds for identifying high-risk groups,48 these biomarker measures are not yet 
used in routine clinical care.  
It is known that CSF tau and Aβ1-42 show promise in discriminating AD from 
healthy controls.61 Patients with low levels of Aβ1-42 and elevated levels of tau protein in 
CSF are significantly more likely to be diagnosed as AD than patients without this 
profile,57,62 although different studies use different cut-offs for abnormal findings. 
Furthermore, the ratio of tau(s) (the indicator of neuronal injury) to Aβ42 has also been 
shown to have good discriminative ability. be highly predictive of cognitive decline in 
   
 
 
10 
cognitively normal cohorts as well as individuals with MCI (odds ratio, 18.1; 95% 
confidence interval [CI], 9.6-32.4) or very mild dementia.60,63  
With the promise of discriminative ability of CSF biomarkers on AD patients 
versus healthy controls and the challenges to define a universal cut-off value of 
biomarker levels, I investigated the potential of using CSF biomarkers (including 
biomarkers from both Aβ and neuronal injury categories) as a combination to develop a 
composite score to predict the risk of progression to AD from MCI in this thesis. 
 
1.2.5 Currently available treatments for MCI patients 
At present, no medication intended for the treatment of MCI patients has been approved 
by the Food and Drug Administration (FDA), although a few studies have been 
conducted to examine the pharmacological treatment of MCI patients. A well-designed 
and high-quality RCT evaluating the effect of donepezil on the progression from MCI to 
AD showed that hazard ratios were lower in the donepezil group compared with the 
placebo group during year 1 (0.42, 95%CI: 0.24-0.76) and during years 1 and 2 (0.64, 
95%CI: 0.44-0.95), but not statically different during the entire three years of the study 
(0.8, 95%CI: 0.57-1.13).37 Several systematic reviews of the use of ChEIs on MCI 
patients produced indeterminate results. Diniz et al.64 found the RR of progression to 
dementia to be 0.75 (95% CI, 0.66 to 0.87) in those treated with a ChEIs compared to 
the placebo group, whereas Raschetti et al.65 showed no significant reduction of the 
progression to AD. Similarly, examining the same RCTs as Diniz et al.,64 Sobów et al.66 
concluded that ChEIs were associated with a reduction of risk of conversion to dementia 
of approximately 20% (odd ratio =0.8, 95%CI: 0.6-0.9) but with considerable concerns 
regarding a substantially increased risk of adverse events and drug discontinuation. 
More recently, a Cochrane review26 reported the treatment effectiveness of ChEIs as 
RRs on delaying the progression from MCI to AD were either borderline significant or 
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significant for the first year (0.69; 95%CI, 0.47-1.00), the first two years (0.67; 95% CI, 
0.55-0.83), respectively or the overall 3 years (RR=0.84; 95%CI, 0.70-1.02). The authors 
concluded that there was modest evidence that ChEIs affect progression to AD in people 
with MCI. This discrepancy may result from the different RCTs included in the pooled 
analysis of that systemic review.  
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1.3 Decision analysis 
Decision analysis has been used for many years as a framework for evaluating the 
tradeoffs inherent in clinical decisions. First, a decision-analytic model is conceptualized 
that describes the sequence of possible consequences associated with alternative 
actions and assigns probabilities for those consequences and values for all of the 
possible outcomes. Evidence about the relative costs, risks, harms, and benefits of 
multiple alternatives faced by a certain patient group can be incorporated into this 
framework to assist decision makers in determining the best use of scarce healthcare 
resources. In this dissertation, we used this method based on several rationales 
suggested by Drummond et al.67 First, decision analysis allows for indirect comparison 
between all comparators that may be unfeasible and costly in an experimental trial 
setting. Second, it allows for the combination of evidence from disparate sources. Third, 
it allows for evaluating long-term outcomes, which would again be unfeasible, costly and 
delay decisions if assessed in experimental trials, but are important for decision making. 
Finally, decision models allow us to conduct sensitivity analyses not only to test the 
assumptions in the model but also to explore what uncertainties are most influential on 
the results.67 
 
1.3.1 Domains of informational value from testing 
Conducting diagnostic, screening, or predictive tests provide clinical value primarily 
because of their ability to change clinical outcomes. For example, if a patient would not 
be treated without the test being done but would be treated when the test is positive (and 
the treatment provides a net benefit for the patient), then the value of testing can be 
quantified by the difference in outcomes with vs. without the test. Some have argued that 
tests can provide value in addition to changing health-related outcomes, such as 
providing reassurance to patients or physicians that a serious disease is absent, the risk 
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of developing a disease in the subsequent years (predictive tests) or knowing for the 
sake of knowing.68-71 Berwick and Weinstein categorized the way people value 
information from tests into four domains based on whether the information is valued by 
the physician (medical) or the patient and their family (non-medical), and whether the 
information is used to make decisions (decisional) or is valued for knowledge sake only 
(non-decisional).69 For physicians, the information with decisional value is the 
information that has impact on their decision, such as the choice of medications or the 
choice to treat or not (i.e., the conventional decision-analytic framework). The 
information with non-decisional value is when the result from a test would not lead 
directly to a medical decision but acts to reassure the physician about their diagnosis 
about a disease. The information for patients with decisional value would impact their 
personal planning, such as financial or family planning that may differ depending on the 
test information. In addition, patients may worry about those who might gain access to 
the test results, such as an insurance company or employer, and would use this 
information against patients’ well-being. Owing to this concern, patients might not be 
willing to undergo testing at all and thus there would be a loss of potential value of 
testing for these patients. The non-decisional value to the patient may represent the 
anxiety about the disease or peace of mind that comes with a favorable result.  
Not only do physicians make treatment decisions based on test results and the 
consultation with patients themselves, but patients who learn about their disease status 
or risk of developing a disease from test results may also make decisions that influence 
the quality of life or financial status of themselves and their families. Conceptually, we 
can quantify the value of a test result as the potential change in outcomes associated 
with actions taken by physicians or patients, though the latter is more difficult in practice. 
In addition, it has been found that test information that is not used at all in decision 
making can still have value for physicians and patients.68,69 Studies have shown that 
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value may be attached to a test that provides information without helping patients or 
physicians make intervention decisions.70 Berwick and Weinstein founded that insured 
pregnant women would be willing to pay $169 out of pocket for an ultrasound test to 
obtain information that is of no decisional use.22 Another recent study also showed that 
patients would be willing to pay $109 to $263 for a predictive test with no available 
treatment23 (no decision possible), such as a genetic testing to predict whether persons 
will eventually develop AD.71 The framework of my thesis focus only on the value 
associated with making medical-related decisions.  
 
1.3.2 Economic evaluation of early identification of MCI and AD 
A few studies have modeled diagnostic strategies for AD patients to examine the 
effectiveness of early assessment and interventions,72-75 but few of them focus on the 
prodromal stage of AD.76 A United Kingdom-based simulation model showed that 
identifying patients in the early stage by the assessment of MMSE could produce 
downstream cost savings and health benefits compared with no early assessment.40 
These findings are consistent with several US-based simulation modeling results of the 
potential benefits of early AD detection, through screening individuals aged 65 and over 
in the various primary care settings followed by treatment.72,76 Furthermore, by 
comparing several biomarker instruments (florbetaben PET or MRI) on the early 
diagnosis of AD, combined with a hypothetical treatment, MCI treatment on AD patients 
would lead to net discounted cost savings of $11,086 per patient over their lifetime in 
direct medical care and $303 in caregiver time, respectively.74  
Delaying the transition from MCI to AD may result in economic benefit.77,78 
Results of a cost-effectiveness analysis using the genetic testing for the presence of 
apolipoprotein (APOE) e4 allele in MCI patients for early intervention showed that 
treating MCI patients with a positive test result with donepezil may be economically 
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attractive with an incremental cost-effectiveness ratio of Can$38,016 per quality-
adjusted life year (QALY).79 That study assumed that donepezil does not delay cognitive 
decline after three years of treatment and no further treatment was provided even if 
patients had develop AD. Those who received donepezil have a higher rate of 
progression to AD in the fourth year than those who do not receive donepezil. Thus, 
these two groups would have an equivalent cumulative probability of developing AD by 
the end of year 4. After year 4, all groups have the same annual probability of 
developing AD.  
 
1.3.3 Value of information analysis 
Decisions based on existing evidence are associated with uncertainty in model 
parameters and thus there is always a chance that a “wrong” decision is made, which in 
turn has health and cost consequences. Value of information (VOI) analysis is an 
approach using Bayesian updating methods to estimate if the chance of making a wrong 
decision is high enough, and if the magnitude of the health and cost consequences are 
great enough, to support conducting new research to reduce our uncertainty surrounding 
all or a subset of the model parameters.80 In the conventional framework of decision 
analysis, the optimal choice between two or more strategies is the one with the highest 
expected value.81 Expected values are based on the best available data, which may be 
imprecise. The result generated is referred to as the expected value given current 
information. The underlying uncertainty in the data introduces the possibility that a 
decision made based on current information is incorrect. However, if we were clairvoyant 
then the optimal decision could be made under all possible values for the parameter sets 
that incorporate parameter uncertainty.   
   
 
 
16 
1.4 Specific aims of my dissertation 
In 2009 the NIA-AA convened three workgroups4,7,12 to explore the need for new 
diagnostic criteria that better reflect the full continuum of AD. All of the recommendations 
incorporate the use of biomarker information.7 They also suggested that it would be 
optimal to treat individuals with subtle evidence of cognitive impairment so as to delay 
the onset of overt clinical symptoms.7 Several CSF biomarkers can provide estimates of 
the risk of developing AD among patients with MCI. My study aims to address the 
following questions: 
1. How is the risk level of MCI patients on the progression to AD defined by CSF 
biomarkers? 
2. What is the optimal strategy to identify and intervene on MCI patients at high 
risk for AD? 
3. What is the value of eliminating uncertainty to inform the question of early 
identification and treatment of MCI patients? 
The overall objective of my thesis is to explore the application of cost-effectiveness 
analysis to assess the use of CSF biomarker testing to identify and subsequently treat 
MCI patients who are at increased risk of developing AD. 
 
The three papers of my dissertation address the following specific aims lined to the three 
questions above. 
1. Build a risk-stratification model that describes the progression from MCI to AD 
according to baseline CSF biomarker results. 
2. Conduct a cost-effectiveness analysis (using a decision-analytical model) of 
treatment strategies for MCI patients with and without CSF biomarker testing.  
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3. Conduct a VOI analysis to estimate the potential value of eliminating or 
reducing the parameter uncertainty in our decision-analytical model (paper 2). 
Risk stratification of MCI patients using CSF biomarker levels could be useful in 
selecting the appropriate interventions. In my first paper I first developed a prediction 
model to estimate the risk of progression from MCI to AD based on MCI patients’ CSF 
biomarker level. In my second paper I developed a decision-analytic model to conduct a 
cost-effectiveness analysis of CSF biomarker testing with subsequent treatment positive 
findings for patients with MCI. In my third paper I conducted a VOI analysis to estimate 
the societal value of reducing parameter uncertainty surrounding the decision model 
through further research.  
Of note, the MCI applied in my thesis specifically refers to aMCI, which was 
designed primarily to detect prodromal AD (Petersen criteria),42,46,47 because the 
symptoms of patients with aMCI are more likely to be AD-induced. Furthermore, the 
RCT conducted by Petersen et al.,(Petersen 2005 NEJM), produced the most favorable 
results of the donepezil treatment effect with aMCI patients as study subjects. 
 
1.4.1 Policy implications 
A question raised by patients with MCI and their family members concerns the likelihood 
and time course of progression to AD. The potential benefits of early identification, such 
as interventions or life planning, to patients, caregivers, and society are unknown. Early 
detection may provide patients and their families an opportunity to plan for the future 
while the affected individual is still able to participate in the decision-making process.82 
Biomarker testing may allow us to predict MCI patients’ risk of developing AD and select 
the appropriate intervention given their risk levels, including pharmacological and/or non-
pharmacological therapeutic approaches. During this early stage, an effective treatment 
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may be beneficial because the cognitive function might be preserved at the highest 
possible level for an extended time.   
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Brief overview  
Background: Cerebrospinal fluid (CSF) biomarkers can distinguish Alzheimer’s disease 
(AD) patients from normal controls; however, their interpretation and potential for use in 
patients with mild cognitive impairment (MCI) remains unclear. 
Objective: To examine whether biomarker levels allow for risk stratification among MCI 
patients who are at increased risk to develop AD, thus allowing for improved targeting of 
early interventions for those whose risk are higher.  
Methods: We analyzed data from the Alzheimer’s Disease Neuroimaging Initiative on 
MCI patients (N=195) to estimate their risk of developing AD for up to 6 years on the 
basis of baseline CSF biomarkers. We used time-dependent receiver operating 
characteristic analysis to identify the best combination of biomarkers to discriminate 
those who converted to AD from those who remained stable. We used these data to 
construct a multi-biomarker score and estimated the risk of progression to AD for each 
quintile of the multi-biomarker score. 
Results: We found that Aβ1-42 and P-tau181p were the best combination among CSF 
biomarkers to predict the overall risk of developing AD among MCI patients (area under 
the curve = 0.77). The hazard ratio of developing AD among MCI patients with high-risk 
(3rd-5th quintiles) biomarker levels was about 4 times greater than MCI patients with low-
risk (1st quintile) levels (95% confidence interval, 1.93-7.26). 
Conclusion: Our study identifies MCI patients at increased risk of developing AD by 
applying a multi-biomarker score using CSF biomarker results. Our findings may be of 
value to MCI patients and their clinicians for planning purposes and early intervention as 
well as for future clinical trials. 
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2.1 Introduction 
Much of the focus of Alzheimer disease (AD) research has turned to the pre-dementia 
stages of the disease. Patients in the prodromal stage of AD, referred to as mild 
cognitive impairment (MCI),1 are at increased risk of developing AD. Evidence has 
emerged suggesting that such individuals2 are most likely to benefit from disease-
modifying therapies once they become available.3,4  
Blood pressure and cholesterol levels provide physicians and patients with a 
quantification of the risk of experiencing heart disease, which can be used to inform 
treatment decisions. Similarly, risk stratification of MCI patients using biomarker levels 
could be useful in identifying higher-risk patients early in the disease course with the 
goal of providing early intervention. While currently available pharmacological treatments 
for MCI patients provide modest benefits in terms of preventing the onset of AD,4-7 
knowledge of a patient’s risk could also trigger care planning strategies for patients and 
their caregivers. 
Several biomarkers have been proposed to facilitate an accurate diagnosis of AD 
during the MCI stage, such as hippocampal atrophy on magnetic resonance imaging 
(MRI), amyloid imaging using positron emission tomography (PET), and changes in 
cerebrospinal fluid (CSF).8,9 CSF concentration of Aβ 1-42 (a biomarker of amyloid 𝛽𝛽 
deposition in the brain) and biomarkers of neurodegeneration, including the CSF 
concentrations of total tau (T-tau) and phosphorylated tau (P-tau181p) proteins, are 
reflected in the currently proposed diagnostic criteria7 for AD and MCI.10 
A National Institute on Aging-Alzheimer’s Association (NIA-AA) workgroup 
proposed criteria for the specific definition of MCI due to AD by combining clinical 
symptoms with CSF biomarker evidence,7,11 denoting the presence of a positive Aβ 
biomarker and a positive biomarker of neuronal injury (T-tau or P-tau181p) as a high 
likelihood that the MCI syndrome is due to AD. Also, the research criteria proposed at an 
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International Working Group (IWG) of dementia experts considered abnormalities in CSF 
biomarkers as one of four supportive diagnostic features of AD.12-14 Both of these groups 
acknowledge the importance of CSF biomarkers in informing the likelihood of the 
progression of AD among MCI patients.15 
Decreased levels of Aβ1-42, and elevated levels of T-tau or P-tau181P in CSF have 
been established as useful indicators for early AD diagnosis.16-19 Although there have 
been several possible cut-off values proposed,5,20-22 there is a lack of agreement on cut-
off thresholds due to the variability in CSF measurements between laboratories23 and 
across techniques.24  
Combining CSF biomarkers into a single score has been shown to better 
discriminate between patients with an AD diagnosis compared with healthy controls than 
an individual biomarker.16,23,25,26 Examples include the Innotest Amyloid-Tau Index (IATI) 
defined by the ratio Aβ1-42 /(240+1.18 x tau),26,27 the AD-CSF-Index,4,16,28 and the ratios 
T-tau/ Aβ1-42 or P-tau181p/ Aβ1-42. These proposed diagnostic algorithms, however, were 
constructed initially to discriminate AD patients from cognitively normal controls but not 
to distinguish between MCI patients who have developed AD over time and those who 
remained stable. We have extended this logic to assess how well a combined prognostic 
biomarker measured at baseline could distinguish between MCI patients who develop 
AD over time and those who do not.  
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2.2 Materials and Methods  
2.2.1 Subjects 
All data were obtained from the AD Neuroimaging Initiative (ADNI) database October 26, 
2013 (https://ida.loni.usc.edu). The ADNI is a non-treatment, observational study aimed 
at setting standards for brain imaging and chemical biomarkers for diagnosis and 
treatment trials. The study was launched in 2003 and is supported by the National 
Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the 
Food and Drug Administration, private pharmaceutical companies, and non-profit 
organizations. The study (ADNI 1) enrolled 192 patients with mild AD, 398 with MCI, and 
229 with no cognitive impairment.29 Six month or one year clinical, imaging, and 
biomarker assessments were conducted over a study period.   
The primary goal of the ADNI is to test whether serial MRI, PET, other biological 
markers, and clinical and neuropsychological assessment can be combined to measure 
the progression of MCI and early AD. We included MCI subjects with complete data on 
CSF biomarkers at study entry in our analysis (N=195). We extracted all assessments at 
baseline and the disease status at each follow-up. 
 
2.2.2 CSF measurement 
The methods for CSF acquisition and biomarker measurement used in the ADNI study 
have been reported previously.22 The CSF concentration of Aβ1-42, T-tau, and P-tau181p 
were measured in the baseline CSF samples using Innogenetics reagents (research use 
only AlzBio3 immuno-assay kits, Ghent, Belgium) and the multiplex xMAP Luminex 
platform (Lumnix Corporation, Austin, TX) at the Penn ADNI Biomarker Core 
Laboratory.30 This is not directly comparable with another commonly used analytical 
platform in European countries, the Innotest (enzyme-linked immunosorbent assay 
[ELISA]).18 More details on data collection of the CSF samples can be found at on the 
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ADNI website (www.adni-info.org). 
 
2.2.3 Statistical analysis 
To examine the presence of selection bias between MCI patients with CSF information 
and those without, we compared baseline demographic and clinical data between 
groups, using a non-parametric Kruskal-Wallis test for continuous variables and 
Pearson’s χ2 test for dichotomous variables. 
Receiver operator characteristic (ROC) curves are standard summaries of 
diagnostic accuracy for continuously valued test results31,32 and dichotomous disease 
status. In our study, however, disease status is defined as the development of AD, which 
can change during follow-up. Accordingly, we used time-dependent ROC analysis to 
characterize the predictive accuracy of CSF biomarkers with continuous values and the 
time-dependent outcome of interest.31,33 Hence, we sought to characterize the 
prognostic accuracy of combinations of CSF biomarkers among MCI patients with 
potential for progression to AD and further estimate the AD risk in terms of CSF 
biomarker values measured at study entry. To our knowledge, this was the first study to 
examine the predictive accuracy of CSF biomarkers on MCI patients using time-
dependent ROC analysis. 
We first fit Cox proportional hazards (PH) models using time to AD as the 
dependent variable and Aβ1-42, T-tau, and P-tau181p as the primary independent variables 
to assess the discriminatory ability of these biomarkers on the progression to AD. We 
summarized the discrimination potential of the combinations of CSF biomarkers, 
measured at baseline (t=0), to distinguish between MCI patients who developed AD by a 
particular time t and those who remained stable by calculating ROC curves for 
cumulative AD cases at each follow-up time t.31  
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Using time-dependent ROC methods we derived combinations of sensitivity and 
specificity by comparing the predicted probabilities of developing AD (estimated from the 
fitted Cox PH model of CSF biomarkers mentioned above) and the actual outcomes at 
each follow-up time (t = 1-6 years). More importantly, censored observations were 
included in the calculation of sensitivity and specificity. For each time t, we calculated the 
area under the ROC curve (AUC (t)), which can be interpreted as the probability that a 
randomly selected MCI patient who developed AD at time t has a larger predicted risk 
than a randomly selected MCI patient who remained stable. We used AUC(t) to examine 
the best combination of CSF biomarkers for longitudinal predictive ability for the 
progression of AD for MCI patients. After the most optimal combination was chosen, we 
used the coefficients from the fitted Cox PH model to construct a multi-biomarker score 
(S) for MCI patients using the following equation: S = Σ(βi × biomarker Ai), where βi 
denotes the estimated beta coefficients for biomarkers Ai. 
We then divided MCI patients into quintiles based on their multi-biomarker 
scores, and computed the cumulative risk of progression to AD for each group using 
Kaplan-Meier methods. We compared the observed risk functions estimated from the 
Kaplan Meier methods graphically to those estimated from Cox PH regression methods 
using the same five groups of patients to assess model fit. 
We then illustrated the longitudinal risk of developing AD for each quintile or risk 
group using Kaplan-Meier methods to establish a prediction model for MCI patients and 
calculate the probabilities of progression to AD by each group at each time point. We 
also calculated covariate-adjusted hazard ratios by incorporating potential confounding 
variables into the Cox PH model. The analyses were done with and without adjustment 
for potential confounding of age, sex, marital status, education level, apoliopoprotein 
(APOE) ε4 alleles carrier status, baseline clinical dementia rating sum of boxes (CDR-
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SB), baseline Mini-Mental State Exam (MMSE) score, baseline Alzheimer’s Disease 
Assessment Scale (ADAS 13) score, baseline hippocampus volume, baseline ventricles 
volume, and the anti-dementia medication history. We further used a multivariate 
backward selection Cox regression model to estimate the impact of the potential 
confounders (p-values for removal from the model was defined as 0.05). 
We used log-rank test to compare the risk of progression to AD among quintiles. 
The proportional hazards assumption was assessed using the log (-log) plots of the 
survival function using Schoenfeld residuals.34 The Wilcoxon (Breslow–Gehan) test was 
performed when hazard functions are thought to vary in ways other than proportionally. 
Risk groups were collapsed if no significantly different risk was presented between 
quintiles. 
We compared the prognostic power of the multi-biomarker score to that of each 
individual CSF biomarker alone and to other diagnostic indices that are commonly used 
such as the ratio tau/ Aβ1-42 (T-tau or P-tau181p), the index described by Hulstaert et al.26 
computed as Aβ1-42/(240 + 1.18 × tau) (T-tau or P-tau181p), and the AD-CSF-index 
developed by Molinuevo et al.16 by applying these indices on the MCI sample in our 
study and then computing the AUC at each time point separately by time-dependent 
ROC analyses described earlier. The latter two indices were constructed using AD 
patients and cognitively normal controls.  
 
All the analyses were done by using Stata version 12 (StataCorp, College Station, TX) 
and R software (version 3.0.3; R Foundation for Statistical Computing, Vienna, Austria) 
with the survivalROC and risksetROC libraries.   
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2.3 Results  
2.3.1 Descriptive statistics 
In total, 195 of 398 MCI patients with complete CSF information at baseline were 
included (Table 2.1). Among those with complete CSF data, the mean age was 74 years 
(range: 67–81 years old), the majority of the sample was men (67%), about 70% 
received no anti-dementia medication at study entry, 2.5% received either 
cholinesterase inhibitors (ChEIs) or menantine, and the rest had no information 
available. The median follow-up period was 30 months (range, 9–58 months). With the 
mean conversion time of 24.5 months, 102 out of 195 MCI patients have converted to 
AD. The cumulative risk of developing AD by 6 years was 66%, which is similar to 
previous studies where 80% of MCI patients developed AD within 8 years.35 No 
significant differences were found between MCI patients with and without complete CSF 
biomarker information at baseline (Table 2.1). (Appendix 2.A presents demographic 
characteristics of MCI patients with CSF information between those who have converted 
to AD and those who remained stable within 6 years). 
 
2.3.2 Time-dependent ROC analysis 
We assessed the discriminatory ability of CSF biomarkers by generating ROC curves at 
annual time points. The results of fitting a Cox PH model with the three biomarkers 
showed that Aβ1-42 and P-tau181p were significantly associated with the risk of developing 
AD (Appendix 2.B). Furthermore, the time-dependent ROC analyses showed no 
difference between the AUC(t) values using the combination of all three CSF biomarkers 
compared with the combination of Aβ1-42 and P-tau181p only (the AUCs were 0.65 and 
0.77 for year 3 and year 6, respectively, regardless of whether T-tau was included or 
not). The combination of Aβ1-42 and P-tau181p discriminated reasonably well among those 
MCI patients who developed AD during follow-up and those who remained stable 
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(Figure 2.1). The AUC(t) values ranged from 0.61 at 2 years to 0.77 at 6 years. 
Accordingly, we chose Aβ42 and P-tau181p to construct the multi-biomarker score in 
patients with MCI.  
 
2.3.3 Predictive discrimination of CSF multi-biomarker score 
We calculated a multi-biomarker score for each MCI patient using the coefficients 
derived from the Cox PH model. The score was calculated as (-0.006) × Aβ1-42 + 0.012 × 
P-tau181p. The mean multi-biomarker score was -0.56 ± 0.49, and the distribution of the 
scores appeared to be bimodal (Appendix 2.C). We divided MCI patients into quintiles 
according to their multi-biomarker score and then estimated the hazard ratio of the 
progression to AD for each quintile relative to the first quintile group (Table 2.2), 
controlling for the baseline risk factors listed in Table 2.1 (the result of fitting initial three 
CSF biomarkers and other baseline risk factors is presented in Appendix 2.D). Among 
the covariates considered, only ADAS 13 score and hippocampus volume showed 
significant impact on the progression to AD.  
The univariate Cox PH model showed a significant difference in the probability of 
progression from MCI to AD between quintiles of the multi-biomarker score (Table 2.3). 
We found that MCI patients with a biomarker score in the third quintile had the highest 
risk of developing AD when adjusting for demographic or MRI imaging variables but not 
cognitive tests. In unadjusted analyses, those with a biomarker score in the fifth quintile 
appeared to have the highest risk. 
 We compared the observed risk of progression to AD by quintiles of the multi-
biomarker score using Kaplan-Meier survival methods (i.e., the cumulative risk of 
developing AD is 1 minus the Kaplan-Meier estimate for the proportion of MCI patients 
remaining stable at time t). The cumulative risk of developing AD by 6 years associated 
with multi-biomarker scores in the 1st through 5th quintile were 33%, 50%, 71%, 81%, 
   
 
 
34 
and 90%, respectively (the log-rank test, p-value <0.0002; the Wilcoxon test, p-value 
<0.0004). We compared the observed Kaplan-Meier survival curves graphically with 
those predicted by the Cox PH model when using the same quintile groups of biomarker 
scores in order to assess model fit (not shown). The model exhibited good fit with the 6-
year risk of developing AD- risk increasing monotonically as the multi-biomarker score 
increased, and the proportional hazard assumption was not violated (p-value = 0.24). 
We found a clear gap between the group of the third, fourth, and fifth quintiles 
and the first and second quintiles (Figure 2.2A), and we found no significantly different 
risk among the top three quintiles by either the log-rank tests or the Wilcoxon (Breslow–
Gehan) test. Thus, we further collapsed the top three quintiles and labeled this group as 
high risk, we labeled the second quintile as intermediate risk and the first quintile as low 
risk. We then estimated the longitudinal variation of cumulative risk on the progression to 
AD (Figure 2.2B), which showed the clear classification of AD risk by multi-biomarker 
scores categorized as three risk levels (high, intermediate, and low) with a follow-up of 
up to 6 years. The univariate Cox PH model using these three risk groups showed a 
significant difference in the probability of progression from MCI to AD (Table 2.4). The 
unadjusted hazard ratio of developing AD among MCI patients with high-risk biomarkers 
levels was about 4 times greater than MCI patients with low-risk levels (95% confidence 
interval [CI], 1.93-7.26), whereas the hazard ratios were 3.5, 2.8, and 2.5 respectively 
when controlling for demographic, cognitive test, and MRI imaging covariates. 
The multivariate backward selection model results indicated that CDR-SB, 
ADAS13 and hippocampus volume were significantly associated with the progression to 
AD in patients with MCI, considering all baseline covariates simultaneously. Other risk 
factors, such as APOE ε4 carrier status and MMSE score did not contribute to the 
explanatory power of the model. However, the hazard ratio for high-risk biomarker levels 
was only about 2 times greater than low-risk levels and was only borderline significant 
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(95% CI, 0.97-4.38) when we adjusted for three significant covariates selected from the 
multivariate backward selection analysis (Table 2.4). 
 
2.3.4 Comparison of discrimination power 
Table 2.5 presents the AUC values at year 3 and year 6 of the time-dependent ROC 
analyses applying several combinations of biomarkers as well as several published 
indices16,26 on the MCI sample in our study. We found no difference in AUC values at 
year 3, whereas AUC values ranged from 0.69 to 0.77 at year 6 (although these results 
were similar). We found that the multi-biomarker score estimated in our study on MCI 
patients and the AD-CSF-index (P-tau) developed by Molinuevo et al.16 that compared 
AD patients to healthy controls were associated with the best AUC value at year 6 
among all tested diagnostic indices that predicted the longitudinal progression to AD. 
Specifically, their discriminative power between MCI patients who converted to AD and 
those who remained stable were 0.77 at year 6. With regards to the remainder of the 
indices, combined biomarkers presented better discriminative ability (higher AUC) than 
individual CSF indices. 
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2.4 Discussion 
Our study sought to enhance the estimation of probability of progression from MCI to AD 
by creating a biomarker-based prognostic index. We found that a combined multi-CSF 
biomarker score, as categorized using quintiles or risk levels, provides a good estimate 
of the risk of developing AD up to 6 years. The hazard ratio of developing AD among 
MCI patients with high-risk biomarker levels was about 4 times greater than MCI patients 
with low-risk levels (95% CI, 1.93-7.26). Furthermore, the result of applying our index on 
AD patients and healthy controls from ADNI 1 (N=216) showed the similar cut-off values 
of quintiles of multi-biomarker scores as those from MCI patients (Appendix 2.E). 
In our case, the combination of Aβ1-42 and P-tau181p showed predictive results 
similar to the combination of all three CSF biomarkers together, which may due to P-
tau181p and T-tau status as neurodegeneration markers. We estimated the AUCs of 
published diagnostic indices developed from AD patients and healthy controls by 
applying those indices to our MCI sample and compared them with the AUC estimated 
with our index. The multi-biomarker score of combing Aβ1-42 and P-tau181p together 
showed better and comparable discriminative abilities than those relying on single CSF 
biomarker and published indices,4,16,26,36 respectively (Table 2.5). However, diagnostic 
indices developed in the previous studies,4,16,26,36,37 may not be applicable to the current 
study since our index was designed based on the MCI population, whereas the former 
indices were based on comparisons between AD patients and healthy controls. The 
interpretation of any comparative results should be made with caution due to the 
heterogeneity of the study populations used in each study.  
We demonstrated that the multi-biomarker score using the ADNI dataset with the 
Luminex-xMAP analytical platform resulted in AUCs and discriminative ability similar to 
those diagnostic indices developed using CSF biomarkers analyzed from different 
platforms or assays (ELISA or mesoscale) applied on AD patients versus healthy 
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controls.4,16,26,27 Moreover, our study used a time-dependent ROC method, which is able 
to capture censored observations in the calculation of sensitivity and specificity better 
than a logistic regression model used in other studies. This approach allowed us to 
accurately evaluate the discriminative capacity of CSF biomarkers measured at baseline 
over time. 
It is well known that decreased Aβ1-42 and elevated tau levels predict progression 
from MCI to AD,18,38-41 but there is a lack of the agreement regarding potential cut-off 
thresholds.24 In other words, individuals with MCI who exhibit low levels of Aβ1-42 and 
high levels of T-tau or P-tau181P have higher risk of developing AD compared to those 
with higher levels of Aβ42 or lower levels of T-tau or P-tau181P, but the relationship 
between quintiles of our index derived from CSF biomarker concentration level and the 
progression of AD on MCI patients might not be ordinal. While the unadjusted data for 
quintiles showed that MCI patients with the composite biomarker score at the top quintile 
had a highest risk, we found that MCI patients with the score at the middle quintile 
tended to have a higher risk of developing AD after adjusting for MRI imaging 
(hippocampus volume and ventricles volume), which was shown to be a good predictor 
of MCI to AD conversion.42,43 This might be attributable to the heterogeneity of the study 
population as well as the discrepant continuum between the pathophysiological process 
of AD and its clinical symptomatology, as studies have shown that altered Aβ 
metabolism precedes tau-related pathology, neuronal degeneration, and clinical 
symptoms.44,45 It is also unclear if the APOE genotype influences the CSF biomarkers-
based risk classification of AD in some studies4,46; however we found no significant 
difference of APOE ε4 carrier status by quintile/risk level groups and no significant 
interaction between APOE ε4 carrier status and quintiles of multi-biomarker scores using 
Cox PH model. Validation in a larger sample would be informative in this regard. 
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The consensus from the Alzheimer’s Biomarkers Standardization Initiative (ABSI) 
is to consider CSF biomarker analysis as a routine clinical test in patients with early-
onset dementia, either at the prodromal stage or with atypical AD.4 With a low frequency 
of complications for lumbar puncture,47 especially in the elderly population,48,49 routine 
analysis of CSF as part of the clinical workup for patients with possible AD has been 
advocated.6,50,51 In addition to pharmacological treatments, other interventions, such as 
cognitive rehabilitation or participation in social activities, are also recommended for MCI 
patients.52 Several cognitive interventions, such as cognitive stimulation, cognitive 
training, and cognitive rehabilitation have shown some effect on improving learning 
abilities and cognition among MCI patients.53 Thus, properly selecting candidates for 
earlier treatment is necessary. Our results showed that MCI patients in the 3rd, 4th, and 
5th quintiles of multi-biomarker score (the high-risk group) were most likely to convert to 
AD, which should qualify them as the primary target population if initiating a treatment 
program MCI patients was applicable. The multi-biomarker score developed in our study 
using an MCI population constitutes a reasonable measure with regard to the risk 
stratification of MCI patients for targeted interventions, such as potentially effective 
treatments or life management strategies. Furthermore, cost-effectiveness analysis for 
CSF biomarkers and subsequent interventions could be performed to show the utility of 
our risk stratification approach to payers as suggested by the ABSI4 by targeting different 
intervention strategies based on the risk level determined by the multi-biomarker score 
here (with accurate diagnosis of MCI as the premise).  
There are limitations to our study. First, neither the baseline biomarker level 
when cognitively normal persons develop MCI nor the disease history of MCI patients 
was known. This might resulted in the non-ordinal risk pattern by quintiles of multi-
biomarker score. It is also possible that the MCI subjects (late MCI)54,55 recruited in the 
first phase of the ADNI were nearing progression to AD, and their biomarker levels were 
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close to the threshold of AD. Further validation studies should be applied on a population 
with relatively early stage of MCI, such as early MCI defined in the second phase of 
ADNI (i.e., objective memory loss documented with scores approximately 0.5-1.5 SD 
below the mean of healthy controls on delayed paragraph recall performance from the 
Wechsler Memory Scale Logical Memory Ⅱ),56 to fully describe the continuum of CSF 
biomarker levels and the disease progression of MCI for better discriminatory 
performance if possible. Second, changes in the concentrations of CSF tau and Aβ1-42 
are early events in the pathogenesis of AD and levels of Aβ1-42 are already fully 
decreased at least 5 to 10 years before conversion to AD, whereas T-tau and P-tau181p 
seem to act as later markers.45,57 This means that patients with MCI may not be an 
optimal target population to apply the CSF analysis since CSF biomarkers (especially 
Aβ1-42) convert to pathologic values several years before the first appearance of clinical 
signs.6 Finally, the current results demonstrate that the discriminatory accuracy of the 
composite biomarker model is not yet clinically satisfactory with an insufficient sample 
size and the heterogeneity of study samples. 
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2.5 Conclusion 
In summary, our study examined the feasibility of distinguishing MCI patients with higher 
risk of developing AD from those at lower-risk through the creation of a multi-biomarker 
score. We did not attempt to define a universal cut-off value on CSF biomarker 
concentration levels, which would be difficult due to assay platforms generating different 
absolute values24 and intra-center or inter-center variability of CSF concentration level.50 
However, we did find similar cut-off results of our index, derived from MCI patients, 
applying on AD patients and healthy control. Our findings demonstrate that MCI patients 
could be effectively categorized into different risk groups of developing AD through the 
use of multiple CSF biomarkers, thus potentially identifying persons with MCI who are 
best suited for pharmacological or non-pharmacological treatment. 
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Table 2.1 Demographic characteristics of the Alzheimer’s disease Neuroimaging 
Initiative (ADNI 1) MCI subjects with and without complete CSF biomarker information at 
baseline.* 
 Covariate 
With CSF data 
(n=195) 
Without CSF 
data (n=203) P-value 
Demographic factors  
  Age, mean + SD, y 74 ± 7 75 ± 7 0.16 
Male, % 66.7 62.6 0.39 
Education, mean + SD, y 16 ± 3 15 ± 3 0.43 
Marital status, %  
 
0.12 
    Married 84.1 76.4 
     Widowed 9.2 14.8 
     Divorced 6.2 6.4 
     Never married 0.5 2.5 
 With Family history of dementia, % 4.6 2.0 0.14
APOE ε4 carrier, % 53.8 52.7 0.82 
Baseline cognitive test, mean + SD  
      MMSE score  26.91 ± 1.79 27.14 ± 1.76 0.33 
    CDR sum of boxes 1.56 ± 0.89 1.64 ± 0.89 0.90 
    ADAS 13  18.85 ± 6.23 18.45 ± 6.32 0.41 
Anti-dementia medications history, %  
 
0.65 
    None 70.3 54.7 
     ChEI only 1.0 1.5 
     Memantine only  1.5 2.0 
     NA 27.2 41.9 
 Baseline MRI volumetric measures   
      Hippocampus volume (mm3) 6,355 ± 1,085 6,448 ± 1,077 0.86
    Ventricles volume (ml) 43,751 ± 24,574 44,266 ± 24,876 0.60 
*No significance different was found in terms of covariates listed above between MCI patients 
with and without complete CSF biomarker information. 
Abbreviation: MCI, mild cognitive impairment; APOE, apolipoprotein E; MMSE, Mini-Mental State 
Examination; CDR-SB, Clinical Dementia Rating–sum of boxes subscale; ADAS-cog, AD 
Assessment Scale–cognitive subscale; MRI, magnetic resonance imaging; ChEI, cholinesterase 
inhibitor; SD: standard deviation; NA, not available. 
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Table 2.2 Hazard ratio of each covariate using the Cox proportional hazards model.*  
Covariate HR SE P-value 
Multi-biomarker score in thea 
     2nd quintile 1.82 0.86 0.206 
  3rd quintile 2.24 1.03 0.078 
  4th quintile 1.79 0.80 0.194 
  5th quintile 1.63 0.81 0.327 
Age 0.97 0.02 0.125 
Male 1.02 0.34 0.949 
Education 0.99 0.04 0.850 
Married (reference) 
     Widowed 0.81 0.39 0.664 
  Divorced 1.63 0.94 0.394 
  Never married 3.82 4.21 0.224 
Having family history of dementia 0.76 0.39 0.591 
APOE ε4 carrier 1.21 0.33 0.491 
Baseline MMSE score  0.95 0.08 0.501 
Baseline CDR sum of boxes 1.29 0.19 0.085 
Baseline ADAS 13  1.09 0.03 0.001 
Baseline hippocampus volume (mm3) 0.999566 0.00 0.005 
Baseline ventricles volume (ml) 1.000003 0.00 0.628 
*N=148. 
aQuintiles were defined by the equation: (-0.006) × Aβ1-42 + 0.012 × P-tau181p. 
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Table 2.3 Proportional hazards model results of patients with MCI by quintiles of multi-biomarker scores.* 
Quintile of multi-
biomarker 
scores 
Unadjusted  
  Adjusted 
   demographica   cognitive testb   MRI imagingc   
 backward 
selectiond 
HR 95% CI   HR 95% CI   HR 95% CI   HR 95% CI   HR 95% CI 
1st quintile (reference group) 
            2nd quintile 1.93 0.86-4.35 
 
1.94 0.85-4.44 
 
1.63 0.70-3.78
 
2.10 0.85-5.16
 
2.03 0.84-4.92
3rd quintile 3.82 1.83-7.99 
 
3.73 1.74-8.02 
 
1.24 1.41-6.79 
 
2.73 1.17-6.33 
 
2.43 1.03-5.71 
4th quintile 3.40 1.64-7.05 
 
3.21 1.49-6.92 
 
2.41 1.11-5.25 
 
2.37 1.03-5.44 
 
1.94 0.85-4.43 
5th quintile 4.10 1.97-8.54  3.73 1.69-8.24  3.03 1.39-6.62  2.44 1.05-5.64  1.93 0.83-4.47 
*The included covariates in each adjusted categories are listed in Table 2.1. 
aCovariates included age, sex, education level, marital status, and APOE ε4 carrier status. 
bCovariates included baseline  MMSE, baseline  CDR sum of boxes, and baseline ADAS 13. 
cCovariates included baseline hippocampus volume and baseline ventricles volume. 
dCovariates included baselines CDR-SB, baseline ADAS13 and baseline hippocampus volumes. P-value for removal from the model was defined 
as 0.05. 
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Table 2.4 Relationship between baseline covariates and the risk of developing AD in patients with MCI. 
Risk levele 
Unadjusted  
  Adjusted 
   demographica   cognitive testb   MRI imagingc   
 backward 
selectiond 
HR 95% CI   HR 95% CI   HR 95% CI   HR 95% CI   HR 95% CI 
Low (reference group) 
            Intermediate 1.93 0.86-4.35 
 
1.93 0.85-4.42 
 
1.63 0.70-3.79 
 
2.08 0.85-5.11 
 
2.02 0.83-4.91 
High 3.75 1.93-7.26  3.53 1.75-7.12  2.8 1.38-5.71  2.5 1.18-5.31  2.06 0.97-4.38 
*The included covariates in each adjusted categories are listed in Table 2.1. 
aCovariates included age, sex, education level, marital status, and APOE ε4 carrier status. 
bCovariates included baseline  MMSE, baseline  CDR sum of boxes, and baseline ADAS 13. 
cCovariates included baseline hippocampus volume and baseline ventricles volume. 
dCovariates included baselines CDR-SB, baseline ADAS13 and baseline hippocampus volumes. P-value for removal from the model was defined 
as 0.05. 
eThe lowest quintile is labeled low risk, the second quintile is labeled intermediate risk, and the top three quintiles are labeled high risk.  
  
   
 
 
49 
Table 2.5 Prognostic power of the AD indices based on CSF biomarkers by time-dependent ROC analysis. 
Index 
AUC  
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Aβ1-42 0.58 0.60 0.63 0.66 0.68 0.74 
P-tau181p 0.63 0.61 0.65 0.68 0.72 0.72 
T-tau 0.54 0.61 0.65 0.68 0.68 0.69 
P-tau181p/Aβ1-42 0.63 0.62 0.65 0.70 0.74 0.76 
T-tau/Aβ1-42 0.57 0.62 0.66 0.70 0.70 0.73 
Hulstaert (P-tau), Aβ1-42/(240+1.18 x P-tau181p)a, 26 0.60 0.60 0.64 0.68 0.71 0.75 
Hulstaert (T-tau), Aβ1-42/(240+1.18 x T-tau)a, 26 0.58 0.61 0.66 0.69 0.70 0.74 
AD-CSF-index (P-tau181p)a,b, 16 0.63 0.62 0.66 0.70 0.74 0.77 
AD-CSF-index (T-tau)a,b, 16  0.57 0.62 0.66 0.70 0.71 0.74 
Current studyc 0.62 0.62 0.65 0.70 0.74 0.77 
aIndices were derived from AD patients versus healthy controls.  
b Aβ1−42−Aβminimum
Aβmaximum−Aβminimum
 −  tau − tauminimum
taumaximum − tauminimum. tau was referred to either P-tau181p or T-tau in this case. 
c(-0.006) × Aβ1-42 + 0.012 × P-tau181p. 
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Figure 2.1 Time-dependent ROC curves by follow-up period and the combinations of 
CSF biomarkers (Aβ1-42 + P-tau181p) estimated from a Cox proportional hazards 
model. TP: true positive = sensitivity; FP: false positive = 1-specificity. 
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B. 
 
 
No. at Risk 
       Low 39  34 26 23 14 10 8 
Intermediate 39 28 20 14 7 7 4 
High 117 81 51 35 10 8 9 
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Figure 2.2 Cumulative probability of AD, according to quintile of multi-biomarker scores 
(Panel A) and risk levels (Panel B). Multi-biomarker scores were classified as low (1st 
quintile), intermediate (2nd quintile), or high (3rd, 4th, and 5th quintiles). The parenthesis 
presented the range the multi-biomarker scores by risk levels.   
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Appendix 2.A The demographic characteristics of converters vs. non-converters among 
MCI patients with CSF biomarker information. 
  
Converter 
(n=102) 
Non-converter 
(n=93) P-value 
Demographic factors    
Age, mean + SD, y 74 ± 7 75 ± 7 0.56 
Male, % 62.7 71.0 0.22 
Education, mean + SD, y 16 ± 3 16 ± 3 0.89 
Marital status, %   0.68 
    Married 84.1 85.3  
    Widowed 9.2 8.8  
    Divorced 4.9 7.5  
    Never married 1.0 0.0  
With Family history of dementia, % 6.9 2.2 0.12 
APOE ε4 carrier, % 61.8 45.2 0.02 
Baseline cognitive test, mean + SD    
    MMSE score  26.62 ± 1.76 27.23 ± 1.78 0.02 
    CDR sum of boxes 1.76 ± 0.94 1.35 ± 0.77 0.00 
    ADAS 13  20.71 ± 5.61 16.86 ± 6.28 0.00 
Anti-dementia medications history, %   0.90 
    None 71.6 68.8  
    ChEI only 1.0 1.1  
    Memantine only  2.0 1.1  
    NA 25.5 29.0  
Baseline MRI volumetric measures     
    Hippocampus volume (mm3) 5,978 ± 998 6,781 ± 1,025 0.00 
    Ventricles volume (ml) 45,077 ± 24,312 42,258 ± 24,955 0.25 
Abbreviation: MCI, mild cognitive impairment; APOE, apolipoprotein E; MMSE, Mini-Mental State 
Examination; CDR-SB, Clinical Dementia Rating–sum of boxes subscale; ADAS-cog, AD 
Assessment Scale–cognitive subscale; MRI, magnetic resonance imaging; ChEI, cholinesterase 
inhibitor; SD, standard deviation; NA, not available. 
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Appendix 2.B Cox proportional hazards model of CSF biomarkers only on predicting the 
progression to AD from MCI. 
CSF biomarker Coefficient SE P-value 
All 3 biomarkers model 
    Aβ1-42 -0.006 0.002 0.006 
  T-tau -0.001 0.002 0.643 
  P-tau181p 0.015 0.007 0.041 
Best combination model   
  Aβ1-42 -0.006 0.002 0.005 
  P-tau181p 0.012 0.006 0.031 
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Appendix 2.C Distribution of multi-biomarker scores with the cut-off value between 
the1st and the 2nd quintile as -1.11, the 2nd and the 3rd quintile as -0.58, the 3rd and 
the 4th quintile as -0.36, and the 4th and the 5th quintile as -0.17. 
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Appendix 2.D Hazard ratios of CSF biomarkers and other covariates using Cox 
proportional hazards model.* 
Covariate HR SE P-value 
CSF biomarkers    
  Aβ1-42 1.00 0.00 0.247 
  T-tau 1.00 0.00 0.351 
  P-tau181p 1.01 0.01 0.452 
Age 0.97 0.02 0.193 
Male 1.04 0.34 0.897 
Education 0.98 0.04 0.712 
Marital status    
  Married (reference)    
  Widowed 0.87 0.43 0.783 
  Divorced 1.75 0.99 0.321 
  Never married 3.07 3.43 0.314 
Having family history of dementia 0.65 0.37 0.443 
APOE ε4 carrier 1.15 0.32 0.623 
Baseline MMSE score  0.94 0.07 0.438 
Baseline CDR sum of boxes 1.33 0.20 0.057 
Baseline ADAS 13  1.09 0.03 0.001 
Baseline hippocampus volume (mm3) 0.999571 0.00 0.005 
Baseline ventricles volume (ml) 1.000004 0.00 0.564 
*N=145. 
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Appendix 2.E Cut-off values of quintiles of using multi-biomarker scores on MCI 
patients versus on AD patients and healthy control of ADNI 1. 
Cut-off  MCI (n=195) AD vs. Control (n=216) 
  1st quintile <-1.11  <-1.23 
  2nd quintile -1.11 to < -0.58 -1.23 to < -0.81 
  3rd quintile -0.58 to <-0.36 -0.81 to <-0.48 
  4th quintile -0.36 to < -0.17 -0.48 to < -0.21 
  5th quintile ≥ -0.17 ≥ -0.21 
 
 
 
 
Chapter 3. Using Cerebrospinal Fluid Biomarker Testing to 
Target Treatment to Patients with Mild Cognitive Impairment at 
Increased Risk of Alzheimer’s Disease: A Cost-Effectiveness 
Analysis 
  
   
 58 
Brief overview 
Objective: Certain cerebrospinal fluid (CSF) biomarkers can identify patients with mild 
cognitive impairment (MCI) who are at different level of risk of progression to Alzheimer’s 
disease (AD). Knowing a patient’s risk level may allow for early interventions for some of 
these patients. The objective of our study was to assess the costs-effectiveness of 
several test-treat strategies using CSF biomarker testing among MCI, compared with 
strategies without testing. 
Methods: We developed a state-transition model to project lifetime AD-free life years, 
quality-adjusted life years (QALYs) and costs for a cohort of 65-year-old MCI patients 
under different test-treat strategies. For the test-treat strategies, we targeted treatments 
based on patients’ risk levels of progression from MCI to AD, whereas strategies without 
testing included no MCI treatment (treat patients only if they convert to AD), and MCI 
treatment (treat MCI patients). We used data from the Alzheimer’s Disease 
Neuroimaging Initiative to incorporate CSF biomarker level-based risk of progression to 
AD. Treatment effectiveness to delay the progression from MCI to AD, derived from a 
systematic review, was 0.84 and continued for 3 years. For AD patients with mild AD 
treatment effectiveness was 0.58 and persisted until patients transitioned to a severe 
stage. We further performed deterministic and probabilistic sensitivity analyses (PSA) to 
evaluate the uncertainty surrounding input parameters. 
Results: The two test-treat strategies were the less effective and less costly compared 
to strategies without testing. The no MCI treatment strategy resulted in the highest cost 
and the highest QALYs with an incremental cost-effectiveness ratio of $29,400 per 
QALY compared to MCI treatment. Treatment effectiveness for patients with mild AD 
and treatment effectiveness for MCI patients were the most important parameters in 
terms of CEA results. The no MCI treatment strategy was associated with 63% 
probability of being cost-effective in the PSA results at willingness to pay of 
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$50,000/QALY. In the post-hoc analysis, the strategy of treating MCI patients at low risk 
was cost-effective with ICER of $39,500/QALY compared with other four primary 
strategies. 
Conclusion: Based on the current evidence, this study illustrates the potential for early 
targeted interventions for MCI patients who are at risk of developing AD, especially for 
those at low risk.  
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3.1 Introduction 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that impairs 
memory, thought, and behavior; reduces quality of life; and decreases survival. An 
estimated 5.2 million people in the US have AD, and it is the sixth leading cause of 
death.1 As age is the most prominent risk factor for the disease, the aging of the 
population in the US will result in an increase to an estimated 7.7 million cases in 2030 
and 11 to 16 million cases in 2050.2 Patients with AD are high users of health and long-
term care services. More than 15 million family caregivers who provide unpaid care for 
people with AD and other dementia in the US are under great psychological and physical 
burden. AD and other types of dementia cost Medicare $113 billion per year and 
Medicaid $37 billion per year. The total annual direct costs of AD are estimated at $214 
billion.1 
Persons with eventual AD may progress through a prodromal stage called mild 
cognitive impairment (MCI)3 or cognitive impairment without dementia (CIND),4 a stage 
characterized by early memory loss but with relatively well-preserved activities of daily 
living, before they were clinically diagnosed as AD. Patients with MCI are at increased 
risk for the development of AD, with an annual rate of conversion to AD of 3-10 percent 
in community-based populations and 10-15 percent in specialty clinics.3,5-9 The MCI 
stage of AD could provide a clinical opportunity for pharmacological intervention with the 
belief that it is more likely to achieve disease modification if interventions could be 
applied earlier in the course of AD,11 or cognitive interventions, such as cognitive 
stimulation, cognitive training, and cognitive rehabilitation.12 Thus, patients with MCI are 
a natural target population to allow proactive, comprehensive management or 
appropriate treatments to be initiated at an earlier disease course or milder level of 
cognitive impairment before the clinical diagnosis of AD.3,13,14 
In clinical practice, physicians order prognostic tests to obtain a better 
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understanding of patients’ risk levels of developing a disease, and have the option to 
intervene if the test result shows a high risk of disease. The improvement in patients’ 
health outcomes from early intervention due to test results, compared to no testing, 
provides a measure of the clinical value of the prognostic test. Specifically, the clinical 
value of test information can be quantified as the difference in health and economic 
outcomes associated with having the test information (where interventions depend on 
the test results) compared to not having the information (where physicians can only 
choose to intervene or not on everyone). Moreover, this value often depends on 
carefully-targeted risk-stratification, because implementation of universal treatment 
programs may be limited by issues of patient acceptance, cost effectiveness, insurance 
coverage, and treatment-related side effects. Risk-stratification holds the prospect of 
achieving high rates of detecting patients who are most likely to develop a disease and 
providing them with effective treatments, while avoiding lower-risk patients from the 
potential side effects or ineffectiveness of treatments. Furthermore, it may also reduce 
overall associated costs. It is not uncommon that interventions in clinical practice are 
usually aimed at high risk or high cost patients who need to be managed carefully and 
proactively. There are no pharmacological treatments approved by the Food and Drug 
Administration (FDA) for patients with MCI;6,15 however, results of randomized clinical 
trials (RCTs)16 and meta-analysis studies17-21 showed modest benefits of cholinesterase 
inhibitors22 (ChEIs: donpezil, galantamine and rivastigmine) on delaying the progression 
from MCI to AD.  
In Paper 1, we examined the predictive ability of multi-biomarker score, 
computed from baseline cerebrospinal fluid (CSF) biomarker levels, to stratify MCI 
patients according to their risk of progression from MCI to AD. The hazard ratio for MCI 
patients with a high-risk score (the 3rd, 4th, and 5th quintiles of the score) or an 
intermediate-risk score (the 2nd quintile) were about 4 (95% confidence interval [CI], 
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1.93-7.26) and 2 (95% CI, 0.86-4.35) times greater than MCI patients with a low-risk 
score (the 1st quintile), respectively. Although the effect size was non-significant when 
comparing the intermediate-risk group to the low-risk group, this was likely due to the 
small sample size of the study used in Paper 1. In this study, we examined the cost-
effectiveness of stratified treatments, defined by the high-, intermediate-, and low- risk 
groups from Paper 1, on MCI patients. We compared the targeted treatments on MCI 
patients based on their risk levels of developing AD defined by the test results of CSF 
biomarkers to no biomarker testing where treatment was either initiated early on MCI 
patients or late when only MCI patients convert to AD.   
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3.2 Methods 
In a cost-effectiveness analysis (CEA) framework, we developed a state-transition 
Markov model to estimate the costs and benefits of targeted treatment on MCI patients 
based on their risk levels of developing AD using test results of CSF biomarkers, and the 
effects of no test results involved. We used results from the primary data analysis and 
published literature to derive relevant parameters in our decision model. Costs and 
outcomes were discounted 3% annually per US recommendation.23 We adopted the 
societal perspective (including formal and informal costs) and a lifetime horizon. 
 
3.2.1 Model structure 
Figure 3.1 illustrates the model structure that computed the effect of testing to stratify 
MCI patients into different risk levels of developing AD combined with or without 
pharmacological treatments compared with treatment strategies without test information 
by simulating a hypothetical cohort of 65-year-old patients with MCI through distinct 
health states defined by the presence of AD severity (mild, moderate, or severe as 
determined by the Clinical Dementia Rating scale) and residential settings (community 
or nursing home). In pre-specified time intervals of one year (the Markov cycle), patients 
could remain in the same health state, transition to another health state or die. MCI 
patients who developed AD would transition to mild AD living in a community setting. 
Each year patients with AD could progress in severity (i.e., from mild to moderate AD or 
from moderate to severe AD) or could transition to a nursing home. Furthermore, once 
AD patients entered a nursing home we assumed that they would remain in the 
institution until death regardless of their disease severity.24 Because patients with severe 
AD are more likely to move from community to nursing home than patients with mild or 
moderate AD and the modest proportion of patients transition to nursing home in the 
mild or moderate AD stage based on the parameters used in our model.. 
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3.2.2 Primary treatment strategies 
We evaluated four treatment strategies for MCI patients. We considered two “test-treat” 
strategies for which CSF biomarker testing was conducted to categorize MCI patients 
into three risk groups (high, intermediate and low) of developing AD defined by CSF 
biomarker score in Paper 1,27and then stratified treatment was decided according to 
patients’ risk levels including treating only the high risk group or treating high or 
intermediate risk groups. We compared these two “test-treat” strategies to alternatives 
without test information, in which no MCI patients were treated (no MCI treatment) or all 
MCI patients were treated (MCI treatment). These four strategies are detailed as follows: 
1) No MCI treatment: treat only if MCI patients convert to AD 
2) Treat MCI patients with high-risk biomarker scores but treatment stops if 
patients convert to AD 
3) Treat MCI patients with high- or intermediate- risk biomarker scores but 
treatment stops if patients convert to AD  
4) MCI treatment: treat all MCI patients but treatment stops if patients convert to 
AD 
The effects of treating MCI patients are to delay the progression from MCI to AD and 
thereby to reduce the associated costs in the AD stages (high utilization of healthcare 
resources). We assumed that if patients received treatment in the MCI stage, they would 
not be eligible for treatment when they convert to AD based on expert opinion, but 
evaluated this assumption in a sensitivity analysis. Similarly, the effects of treating AD 
patients was to delay the progression to more severe dementia stages and indirectly 
reduce the probability of nursing home placement because the transition from 
community to nursing home is conditional on the disease severity.  
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3.2.3 Parameter sources  
We used results from the primary data analysis using data of the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI-1),28 published literature, and meta-analyses20 to derive 
the predictive risks for progression from MCI to AD, mild to moderate AD, and moderate 
to severe AD, and the estimates of the impact of treatments on disease progression in 
the MCI and AD stages. Table 3.1 summarizes the parameter estimates and their 95% 
confidence intervals (CIs). Furthermore, we characterized the quality of studies from 
which input parameters were derived (Appendix 3.A),29 the quality of studies, evaluated 
based oh three dimensions: study design, internal validity, and external validity, are good 
in the aspect of study design, fair in the internal validity (4 out of 23 studies are low or 
poor), and low quality in the external validity, respectively. 
 
3.2.3.1 Disease progression  
We assumed all transitions occur in the middle of each year, with transitions from MCI to 
the mild AD stage occurring first, followed by transitions from mild to moderate or severe 
AD. Death can occur from any health state and individuals could only experience one 
transition in a year (model cycle), such as from MCI to mild AD, mild to moderate AD, or 
moderate to severe AD.25 
We estimated the annual transition probabilities from MCI to AD contingent on 
the risk groups (high, intermediate, and low) defined by CSF biomarker scores using 6-
year follow-up data from the ADNI (Paper 1). In brief, we summarized baseline CSF 
biomarker levels into a multi-biomarker score27 and defined three risk groups: high risk 
(defined by the 3rd, 4th, and 5th quintiles of the multi-biomarker score), intermediate risk 
(the 2nd quintile), and low risk (the 1st quintile). We calculated the cumulative probability 
of progression to AD for each risk group using the Kaplan-Meier survival function. For 
each risk group, we converted the 6-year cumulative probability into an annual 
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probability of developing AD and used this annual probability in our decision model and 
assumed it to be constant over time.  
For transitions among AD stages, we used more recent/updated probabilities 
estimated by Spackman et al. using data from the Uniform Data Set (UDS) of the 
National Alzheimer Coordinating Center (NACC),24 which includes patients receiving 
contemporary AD care. Spackman et al. provided estimates of the stage-to-stage 
transitions and community to nursing home transitions conditional on AD stage 
separately. We computed the combined stage and nursing home transition probabilities 
(e.g., moving from mild AD residing in a community setting to moderate AD residing in a 
nursing home) by multiplying stage-to-stage and community-to-nursing home transitions 
for each possible combination of disease severity and residential setting (Table 3.1 & 
Appendix 3.B). In Spackman’s study, disease stage-to-stage transitions were assumed 
to occur independently of setting, whereas nursing home transitions were conditional on 
the disease severity.24,30 
 
3.2.3.2 Treatment effectiveness  
We derived estimates of treatment efficacy of ChEIs separately for MCI patients and AD 
patients. The effectiveness of treatment was modeled as the reduction of the annual 
transition probability by a percentage, defined by a relative risk (RR). For MCI patients, 
we multiplied the transition probabilities of developing AD by the RR to estimate the 
potential impact of treatment on delaying the progression from MCI to AD. Similarly, the 
effectiveness of treatment for AD patients was measured by the reduction of the 
following transition probabilities by a percentage: from mild to moderate AD, mild to 
severe AD, and moderate to severe AD. We further assumed that, given an AD severity 
stage, that treatment had no effect on the transitions from community to nursing home. 
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However, because treatment affected the progression through the AD severity stages, 
there was an overall reduction in nursing home placement among the treated patients. 
The effectiveness of treating MCI patients with ChEIs was derived from a recent 
Cochrane review20 (the comparison with other systematic reviews of ChEIs on MCI 
patients is shown in Appendix 3.C). That review reported an effectiveness of ChEI 
treatment for MCI patients of 0.69 (95% CI, 0.47-1), 0.67 (95% CI, 0.55-0.83) and 0.84 
(95% CI, 0.7-1.02) for years one, two and three, respectively. We used the 3-year effect 
of 0.84, which presented 16% risk reduction on the progression from MCI to AD and 
assumed that this persisted for only three years of treatment.  
The effectiveness parameter of ChEI treatment was 0.58 (95% CI, 0.35-0.76) 
and 0.95 (95% CI, 0.64-1.41) for patients with mild AD or moderate AD, respectively. 
The RR applied to patients with moderate AD was derived directly from an RCT,35 
whereas we used the 0.8 (95% CI, 0.5-1.2) MMSE (mini-mental state examination) point 
increase over two years among AD patients with donepezil treatment from the same 
RCT to compute the treatment effectiveness (RR) for patients with mild AD. We 
simulated the trial cohort over two years and calculated the average MMSE (the clinically 
defined ranges for mild and moderate AD) for the treatment and control groups, and then 
derived the reduction in annual progression, measured as RR, from the mild to moderate 
stage that would yield a 2-year difference of 0.8 in the average MMSE scores while 
directly using the RR of 0.95 from the same RCT for the reduction in annual progression 
from the mild to severe, and the moderate to severe stages. The average MMSE score 
for the mild, moderate and severe stage was 24, 14, and 6, respectively. The trial cohort 
included 51% patients with mild AD and 49% patients with moderate AD, and the annual 
progression from the mild to moderate, the mild to severe, and the moderate to severe 
were 0.167, 0.014, and 0.299 (Table 3.1).  
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Owing to the limited evidence from clinical trials16 and meta-analysis studies,17-21 
we assumed the treatment effect duration for MCI patients persisted for only 3 years. 
Conversely, the effect of ChEI treatment initiated for AD patients was assumed to 
continue until either they discontinued therapy due to adverse events or moved to the 
severe stage where the treatment was terminated. The reason we stopped treatment for 
severe AD patients was because our treatment parameters were derived from the 
largest clinical evidence base reviewed by Bond et al.,36 and treatment is only approved 
by the FDA for mild or moderate AD patients. We did not consider the residual effect 
from treatments. 
 
3.2.3.3 Adverse events (AEs) associated with treatment  
The AEs associated with ChEI treatment included diarrhea, nausea, cramps, headache, 
and serious AEs as reported in prior RCTs.20 The reported increase in the risk of AEs 
due to treatment between the treatment and the control groups for MCI and AD patients, 
which were 1.09 (95% CI, 1.02-1.16)20 and 2.51 (95% CI, 2.14-2.95),37 respectively. 
Also, the result from a systematic review38 of the annual risk of AEs in the placebo arm 
of donepezil trials for MCI patients was used as the baseline risk (0.23). The annual risk 
of AEs associated with treatment was computed as 0.23*1.09 = 0.25 and 0.23*2.51 = 
0.58 for MCI and AD patients, respectively. Among MCI or AD patients with treatments, 
25% or 58% of them would experience treatment-induced AEs compared to 23% for 
those who had no treatment, respectively. We applied the risk difference between the 
treatment and the control groups (0.25-0.23=0.02 and 0.58-0.23=0.35 for MCI and AD 
patients, respectively) in the model, which means that we only allowed treated patients 
to experience an AE. Once the treatment terminated, no AE event occurred in the 
model.  
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3.2.3.4 Adherence 
Results from a systematic review37 of 10 RCTs examining the efficacy of ChEIs among 
AD patients showed that more patients discontinued therapy due to AEs in the treatment 
group (18%) than in the placebo group (8%) with the study period of 6 months for all but 
two studies. We derived the withdrawal rate due to treatment-induced AEs as the 
difference in withdrawal rates between the treatment and the control groups, which was 
about 10% (95% CI, 7-13%) per 6-month span. Furthermore, we extrapolated the 6-
month rate into an annual rate and derived an annual withdrawal probability of 19% 
(95% CI, 14-24%) conditional on experiencing an AE. We applied this annual probability 
derived from AD patients to MCI patents. We also calculated the annual probability of 
withdrawal from treatment due to other reasons (excluding AEs) as 4.9% (95% CI, 3.7%-
6.3%) and applied this probability to both MCI and AD patients receiving treatment.  
 
3.2.3.5 Health utilities  
Our health outcome measure is quality-adjusted life years (QALYs), as recommended by 
the Panel on Cost-Effectiveness in Health and Medicine.39 QALYs are a composite 
measure of survival (longevity) and quality of life, where survival time is weighed by 
individuals’ health-related quality of life, as measured by health utilities.40 Individuals in 
perfect health are assigned a health utility value of 1, with lower values representing 
worse quality of life and a value of 0 representing dead. 
We assigned utilities by disease severity and residential settings based on 
analyses by Neumann et al,31,41 because it was one of the few studies that estimated 
health utilities for joint states defined by disease severity and residential settings. Due to 
the absence of range of utilities by residential settings reported in their study, we applied 
the estimates of the SD for AD patients dwelling in the community to AD patients in the 
nursing home. In addition, we also accounted for the disutility resulted from the AEs due 
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to the treatment. We used the point estimate from other studies, such as the AEs due to 
aspirin,43 because the majority of AEs reported in the clinical trials were mild.20,37  
 
3.2.3.6 Excess mortality 
The annual excess mortality rate among patients with severe AD was estimated at 0.11 
by the additive model.44,45 We assumed that patients with moderate AD would 
experience half of the excess rate (i.e., we added 0.11/2 to the background death rates 
for patients with moderate AD). We assumed that this additive effect is the same 
regardless of the patients’ age or gender.44 Accordingly, the mortality risk in each 
disease stage for AD patients was estimated by combining the age-specific, all-cause 
mortality rates46 with an additive effect of 0.055 for patients with moderate AD and 0.11 
for patients with severe AD. We assumed that the mortality rate for MCI patients and 
patients with mild AD are equal to the background all-cause mortality rate. 
 
3.2.3.7 Cost 
All cost estimates were inflated to 2013 US dollars with the use of the consumer price 
index (CPI)47 if needed. Moreover, in order to be able to apply the cost estimated from 
European countries if any, costs in the local currency were converted to the 
corresponding US dollars using the gross domestic price purchasing power parity (GDP-
PPP) conversion rates48 and further inflated to the 2013 US dollars using the CPI. 
 
3.2.3.7.1 Formal and informal care 
While many studies to date have assessed the economic burden of dementia (including 
AD and other type dementia),49-53 few report costs by disease severity together with 
residential settings, as needed for our model. In the US setting, only Rice et al.54 and 
Leon et al.55 reported AD costs by these two attributes, however, they were published 
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almost twenty years ago so that may not represent current practice. The most recent 
studies were conducted outside the US,56,57 which would not be pertinent to our analysis 
due to differences in healthcare systems and culture. Moreover, few recent meta-
analyses49,52,53 comparing cost-of-AD studies (categorized by disease severity or 
residential settings, or both) were available, however, the studies conducted in the US 
were done before 2000,58-60 and their cost estimates were in the range of our cost 
parameters, or no cost information applicable to our study.61-64 Accordingly, we used the 
cost estimates as reported by Leon et al.,55 which included data from 9 states with a 
larger sample size (n=674).  
In the Leon study, summaries for community-based dwelling, institutionalization 
(assisted living and nursing home), formal (defined as paid health services) and informal 
care (defined as unpaid care provided by a primary family caregiver) and costs by 
disease severity were reported separately. The cost of informal caregiving was measure 
by the amount of time spending on the aspect of activities of daily living (ADL) and 
instrumental activities of daily living (IADL). Hours of care were multiplied by national 
hourly wage rates for ADL and IADL, respectively. We converted monthly costs from the 
study to annual costs and assigned them to the comparable health states in our model. 
Due to the lack of the variance (95% CI) of costs reported in the study, we further 
assumed that the cost estimate for each health state in the model was 50% lower or 
higher from the mean of point estimates as the lower bound and the upper bound, 
respectively. 
For the costs incurred in the MCI stage, we used data from Luppa et al.65 to 
inform direct costs, including medical cost, pharmaceuticals, and non-medical costs 
(home care, assisted living, and transport), for patients with MCI, albeit it was not 
significantly higher when compared with patients without cognitive deficit.  
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We didn’t account for the indirect costs resulting from the loss of productivity of 
patients due to the advanced age. The CEA results presented included both formal and 
informal costs unless specified. 
 
3.2.3.7.2 Medication 
We based the unit costs for AD medications on the average wholesale price reported in 
the Red Book.66 The daily costs for these drugs were estimated based on their 
recommended dose and usage from the licensed labels. We estimated the medication 
cost at the lowest available market price ($7.79) per day (the cost for donepezil 5mg is 
the same as 10mg) and largest pack size. We estimated the annual drug costs as 
365.25 × 7.79 = $2,845. For the follow-up cost due to the treatment, we continued the 
assumption made by previous study31 that donepezil would induce two and one extra 
office visits every year along with the treatment effect duration for MCI and AD patients, 
respectively. The one office visit was associated with $81 as estimated by the previous 
study.31 
 
3.2.3.7.3 CSF biomarker testing 
The cost of CSF biomarker analysis, a one-time cost per patient, was estimated using 
the cost data from Centers for Medicare & Medicaid Services hospital outpatient fee 
schedule as reported in the previous study.67  
 
3.2.4 Analysis 
3.2.4.1 Base-case analysis 
We calculated expected discounted lifetime costs and discounted QALYs for each of the 
four strategies. Cost-effectiveness results were presented as the incremental cost-
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effectiveness ratios (ICERs), measured as the additional cost for per additional QALY 
gained (∆c/∆e)40 by the following steps: 
1) We ranked strategies by increasing total cost and eliminated strongly 
dominated strategies. A strategy is strongly dominated if it is more costly but 
less effective than another strategy.  
2) We calculated the ICER for each non-dominated strategy compared to the 
next most expensive non-dominated strategy. 
3) We identified and eliminated all weakly dominated strategies. A strategy is 
weakly dominated if it has a higher ICER than a more costly strategy, 
indicating that the strategy is more costly and less effective than a 
combination of other strategies.  
4) ICERs are recalculated after removal of a weakly dominated strategy. This 
process may need to be iterated when there are several weakly dominated 
strategies. 
5) We compared the remaining ICERs with a willingness to pay (WTP) threshold 
for a QALY, which we varied from $50,000 to $100,000 per QALY. The 
strategy with the highest ICER that is lower than the designated WTP is the 
most cost-effective strategy.  
 
3.2.4.2 Sensitivity analysis 
In addition to the base-case analysis, we conducted deterministic (using discrete 
alternative values in the simulation) and probabilistic sensitivity analyses, where all input 
parameters are simultaneously varied by sampling from probability distributions for each 
parameter, to evaluate uncertainty with respect to the parameter assumptions. The 
specific description of how we derived the value or range of each input parameters is 
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presented in the above section of 3.2.3 and the characteristics of each parameter are 
shown in Table 3.1. 
 
3.2.4.2.1 Deterministic sensitivity analysis 
In the deterministic sensitivity analysis (DSA), we varied one parameter at a time (one-
way) or two parameters simultaneously (two-way) to recalculate lifetime costs and 
QALYs for each treatment strategy, and then determine which parameter is more 
influential to the CEA results, defined as the widest range of recalculated ICERs and 
also crossing a decision threshold. We drew upper and lower bound values of each 
parameter from published 95% CI estimates or used 50% value lower or higher to the 
mean if not available. 
 
3.2.4.2.2 Probabilistic sensitivity analysis 
We conducted the probabilistic sensitivity analysis (PSA) using second-order Monte 
Carlo repeat sampling methods68 in which values of all input parameters were randomly 
drawn from the distributions simultaneously to account for the parameter uncertainty. We 
used beta distributions to represent uncertainty in the probability and utility parameters 
because such estimates are constrained on the interval [0, 1]. We characterized 
uncertainty in RR estimates using the log-normal distribution and we used gamma 
distributions to reflect uncertainty in costs, which have a lower bound at 0 and are 
generally right-skewed.69 Table 3.1 presents probabilistic input parameters and their 
corresponding distributions. Uncertainty around these parameters was considered 
simultaneously and the parameters were entered into the model as pre-specified, 
independent distributions except health utilities. To ensure only meaningful scenarios, 
we required that the rank order of QALY weights (i.e., utilities) in each PSA iteration was 
aligned with disease severity and residential settings,42 which implied that the health 
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utility of u(MCI) > u(mild AD) > u(moderate AD) > u(severe AD) and u(community) > 
u(nursing home). In this model, we applied the preference ordering algorithm developed 
by Goldhaber-Fiebert and Jalal70 to ensure the health utility drawn in the PSA was 
presented in the preferred order by the disease severity and the residential settings.  
 Fixed input parameters included the treatment effect duration for MCI patients 
(fixed at a 3-year interval), the excess mortality rate due to AD, and discount rates of 
costs and health outcomes. We conducted 10,000 PSA iterations. We presented the 
PSA results using the cost-effectiveness acceptability curve (CEAC),71 which depicts the 
percentage of times that a strategy is cost-effective in the PSA iterations at different 
WTP thresholds.  
The PSA simulation result was also used to present the result of the base-case 
analysis as the means of discounted life time costs and QALYs for each strategy to 
account for the nonlinear feature of Markov model used in the current study, in which the 
input parameters should ideally be modeled with probability distributions instead of point 
estimates (the mean) because the a model outcome, f(x), is a nonlinear function of input 
parameters, x, so that the expected value of f(x) is not equal to the function of the 
expected value of x (point estimate).68,72 
 
3.2.4.3 Scenario analysis 
We constructed treatment scenario analyses by varying treatment assumptions in the 
MCI and AD stages. In a best-case scenario, we applied the assumption that the 
patients would receive treatment when they convert to AD regardless of their treatment 
status in the MCI stage to the four primary treatment strategies. Next, we considered the 
treatment scenario conditional on the disease course of AD (MCI, AD or both), 
assuming: 1) all patients would be treated in both MCI and AD stages (treat both), and 
we varied the effectiveness of treatment at the AD stage among those patients who were 
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also treated in the MCI stage, 2) treat all MCI patients but treatment stops if patients 
convert to AD (treat MCI only), and 3) treat only when MCI patients convert to AD (treat 
AD only). Finally, we considered a scenario no treatment was initiated in either the MCI 
or AD stage (treat neither).  
 
 
All analyses were performed in TreeAge (version TreeAge Pro 2013, TreeAge Software, 
INC, Williamstown, Mass), and Microsoft Excel (Microsoft Corp., Redmond, WA).
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3.3 Results 
3.3.1.1 AD-free life time 
The AD-free life time provides a measure of the average duration of time patients spend 
without AD under the different strategies. We found that AD-free life years associated 
with no MCI treatment was 3.60 years. Treating MCI patients at the high-risk level , 
treating only those at the high- or intermediate-risk level, or treating all MCI patients 
produced an extra 1.6, 2.3, and 3.3 AD-free life months compared to no MCI treatment. 
Specifically, Figure 3.2 displays the AD-free months gained by MCI treatment compared 
with no MCI treatment (95% credible interval: 0.77-5.74). 
 
3.3.1.2 Base-case analysis 
As shown in Table 3.2, the base-case results indicated that the two test-treat strategies 
were less costly and less effective than the other two strategies with no testing. 
Moreover, treating MCI patients at high risk was weakly dominated because it had a 
higher ICER than the MCI treatment strategy. No MCI treatment resulted in the highest 
cost and the highest effectiveness (QALYs), with an ICER of $29,400 per QALY 
compared with MCI treatment. The increased cost associated with no MCI treatment is 
because patients with AD are associated with high healthcare use; the increased 
effectiveness resulted from the better treatment effectiveness for patients with mild AD 
than for MCI patients. 
We decomposed the total discounted lifetime costs and total discounted QALYs 
generated by each strategy by disease severity and residential settings. The cost 
accumulated in each disease stage/residential setting was increased with the weighted 
time (QALYs) spent in that state (health utility stands for the weight for each health state 
defined by the disease severity and residential setting). MCI treatment was associated 
with the greatest AD-free life years gained but with a shorter discounted quality-adjusted 
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time spent in the mild AD/community state, whereas no MCI treatment exhibited the 
longest time in the mild AD/community state (Appendix 3.D & 3.E). 
 
3.3.2 Sensitivity analysis 
3.3.2.1 Deterministic sensitivity analysis  
Because the two strategies with testing information (treat high, and treat high or 
intermediate) were not cost-effective in any scenario where all possible values of point 
estimates for parameters were applied, we presented the results of DSA by simply 
comparing MCI treatment and no MCI treatment strategies.  
 
3.3.2.1.1 One-way DSA 
The tornado diagram (Figure 3.3) showed that the CEA result was sensitive to treatment 
effectiveness for patients with mild AD, treatment effectiveness for MCI patients, health 
utility for patients with mild AD living in the community, informal and formal costs in the 
mild AD/community state, and the annual risk of transition to nursing home for patients 
with mild AD. We further searched for the threshold of a parameter that a preferred 
strategy would switch from no MCI treatment to MCI treatment at WTP of 
$50,000/QALY. Specifically, MCI treatment became cost-effective when the RR of 
treatment effectiveness for MCI patients was less than 0.77 (base-case value, 0.84) 
(Appendix 3.F), the RR of treatment effectiveness for patients with mild AD was greater 
than 0.66 (base case value, 0.58) (Appendix 3.G), the excess mortality rate due to 
severe AD was less than 0.27 (base-case value, 0.11) (Appendix 3.H), and the overall 
annual risk of progression from MCI to AD reduced 50% (Appendix 3.I), in which the 
probability for MCI patients at high risk decreased from 0.244 to 0.122, for patients at 
intermediate decreased from 0.108 to 0.054, and for MCI patients at low risk decreased 
from 0.065 to 0.033. We did not find a threshold value when we varied the duration of 
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treatment effect on MCI patients (up to 10 years) (Appendix 3.J), the annual cost of 
medication (down to $100 per year) (Appendix 3.K) or varied the time horizon of the 
analysis (range, 10-35 years) (Appendix 3.L).  
 
3.3.2.1.2 Two-way DSA 
In addition to varying one parameter at a time, we conducted two-way DSA by varying 1) 
treatment effectiveness for MCI patients vs. treatment effectiveness for patients with mild 
AD, and 2) the duration of the treatment effect on MCI patients vs. treatment 
effectiveness for patients with mild AD. Results in Appendix 3.M shows the 
combinations of these parameters for which MCI treatment is cost-effective at WTP of 
$50,000/QALY. On the other hand, in order for no MCI treatment to remain as the 
optimal strategy, the RR of treatment effectiveness for patients with mild AD would need 
to ≤ 0.6 if MCI patients have received treatment for 6 years (Appendix 3.N).  
 
3.3.2.2 Probabilistic sensitivity analysis 
Figure 3.4 presents the probability that each strategy is cost-effective for varying values 
of WTP (i.e., the CEAC). Specifically, no MCI treatment was cost-effective with 63% of 
time in the PSA simulation (10,000 iterations) over 37% of time for the MCI treatment 
strategy at WTP of $50,000/QALY. Given the current evidence, however, the treat high 
risk and treat high or intermediate risk strategies have shown relative low chances to be 
cost-effective compared with strategies of MCI treatment and no MCI treatment. They 
had a limited chance to be cost-effective when WTP is higher than $30,000/QALY. 
Moreover, in addition to the probability of being the cost-effective strategy, the 
incremental cost-effectiveness plane illustrated the considerable variation of the 
simulated results based on 10,000 iterations. Here, we presented the joint distribution of 
incremental costs and QALYs between no MCI treatment and MCI treatment strategies 
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(Appendix 3.O).  
 
3.3.3 Scenario analysis 
3.3.3.1 The best-case scenario 
In addition to the base-case analyses where we assumed that if MCI patients have 
received treatment, they would not be treated when they convert to AD, Table 3.3 
presents the CEA results of all treatment strategies assuming that treatment would be 
allowed when patients convert to AD regardless of their treatment status in the MCI 
stage. As expected, the QALYs increased with the increasing number of treated MCI 
patients and the strategy of treating all patients both in MCI and AD stages (MCI 
treatment) was associated with the highest cost and highest QALYs, with an ICER of 
$28,100 per QALY. The CEAC showed that the probability that MCI treatment is cost-
effective is 77% at a WTP of $50,000/QALY (Appendix 3.P). A one-way sensitivity 
analysis of this scenario showed that treating only when MCI patients convert to AD (no 
MCI treatment) would be cost-effective over the other three strategies if the RR of the 
treatment effectiveness for MCI patients were greater than 0.91 (base-case value, 0.84) 
(Appendix 3.Q). While varying the treatment effectiveness for patients with mild AD in 
the strategy of treating all patients both in the MCI and AD stages but holding it at the 
base-case value (RR=0.58) in the other three strategies, the strategy of no MCI 
treatment was cost-effective when the RR of the treatment effectiveness for patients with 
mild AD, which was changed only in the strategy of treating all patients both in the MCI 
and AD stages, was greater than 0.66 (Appendix 3.R). 
 
3.3.3.2 Comparison of treatment scenarios 
Next, we considered the treatment scenario conditional on the disease course of AD 
(MCI, AD or both). Without considering the test-treat strategies, we compared treat MCI 
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only and treat AD only to the treat both and treat neither scenario. Table 3.4 shows that 
scenarios with treatment produced more QALYs and costs compared to no treatment. 
Among those scenarios with treatment, treat AD only produced more QALYs but also 
cost more than treat MCI only, and treat both was the scenario with the highest QALYs 
and costs with an ICER of $28,700/QALY. 
Table 3.4 also shows a trade-off among MCI, mild AD, and severe AD stages 
occurred between treat MCI only (MCI treatment) and treat AD only (no MCI treatment) 
scenarios with regard to QALYs gained by the disease severity. We found that patients 
would spend more weighted time (QALYs) in the MCI and the severe AD stage if they 
received the treatment in the MCI stage, whereas the amount of weighted time spent in 
the severe AD stage was reduced if they received treatment only if they convert to AD. 
Furthermore, treatment initiated in both MCI and AD stages produced more QALYs in 
the MCI stage but less QALYs in the moderate AD stage compared to the other 
strategies.  
Our base-case results implied the net benefits of treating MCI patients with high-
risk scores (the difference between treating only when MCI patients convert to AD [no 
MCI treatment] and treating MCI patients at high risk) and treating MCI patients with 
intermediate-risk scores (the difference between treating MCI patients at high or 
intermediate risk and treating MCI patients at high risk) produced fewer QALYs and was 
less costly; however, the net benefit of treating MCI patients with low-risk scores (the 
difference between treating all MCI patients [MCI treatment] and treating MCI patients at 
high or intermediate risk) generated more QALYs and was more costly. Due to this 
finding, it may be beneficial to target treatments on MCI patients with low-risk scores as 
priority. In this post-hoc analysis, we examined the scenario of treating MCI patients at 
low risk of developing AD, including two additional strategies - treat MCI patients with 
low-risk score and treat MCI patients with low- or intermediate-risk score. CEA results 
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showed treating MCI patients at low risk was cost-effective with an ICER of $39,500 in 
this case (Appendix 3.S). Appendix 3.T shows the results for which treatment strategy 
would be cost-effective at WTP of $50,000/QALY by varying parameters of treatment 
effectiveness for patients with mild AD and treatment effectiveness for MCI patients 
simultaneously. No MCI treatment and MCI treatment were more likely to be cost-
effective compared to strategies of treat low and treat low or intermediate with a greater 
region of being preferable. Similarly, PSA results based on this scenario showed that no 
MCI treatment strategy was associated with 37% probability of being optimal at WTP of 
$50,000/QALY, whereas it was 30% and 21% for treating all MCI patients and treating 
MCI patients at low risk, respectively. Strategies of no MCI treatment and treat low were 
intersecting at WTP of $80,000/QALY (Appendix 3.U). Appendix 3.V presents the CEA 
results based on the assumption that patients would be treated regardless of their 
treatment status in the MCI stage. Similar to the primary treatment strategies, treat all 
patients both in the MCI and AD stages (MCI treatment) was cost-effective with an ICER 
of $28,100/QALY. 
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3.4 Discussion 
In this study, we aimed to assess the costs and benefits of the use of CSF biomarker 
testing to target treatments for MCI patients to delay the progression of AD compared 
with no testing where treatment was either initiated on all MCI patients or only when MCI 
patients convert to AD. We did not find that CSF biomarker testing added value to guide 
the decision whether or not to target treatments for MCI patients at higher risk in the 
primary analysis. While the biomarker results did allow us to distinguish high-risk 
patients from those at lower risk in Paper 1, there was no added benefit from stratified 
treatments for MCI patients at higher risk. This might be because we did not find 
satisfactory evidence of risk estimates on disease progression from MCI to AD by CSF 
biomarker scores in Paper 1. This could have been due to the study sample included in 
Paper 1, which included a high proportion of MCI subjects who were close to 
transitioning to AD.28,73 Also, neither the baseline biomarker scores at the time that 
cognitively normal controls had developed MCI nor the natural history of disease among 
MCI subjects was available for the adjustment of risk estimates. Thus, our CEA results 
may be most relevant for populations who are more proximal in time to the clinical 
diagnosis of AD. Moreover, we took a conservative perspective on the assumption of the 
treatment effectiveness for MCI patients due to the modest results from published 
studies.20 This resulted in reduced benefit for targeting MCI patients base on their risk 
levels of developing AD compared with treating only when they convert to AD and 
consequently decreased the chance of being preferred for those strategies that targeted 
patients based on their risk levels. However, it is likely that MCI subjects enrolled in 
clinical trials that examined the treatment efficacy of ChEIs were heterogeneous and 
thus resulted in indefinite outcomes.6 With increasing refinement of diagnostic tools, our 
results may present different findings showing the potential value of biomarker testing.  
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On the other hand, CSF biomarker testing may be of value if treating MCI 
patients at low risk rather than those at high risk, as shown in our post-hoc analysis. 
CEA results in this scenario indicated that treating MCI patients with low-risk biomarker 
scores was cost-effective. In contrast, PSA results showed that treat low strategy was 
associated with lower chance of being preferable compared with strategies of MCI 
treatment and no MCI treatment. Strategies of treat low and no MCI treatment were 
intersecting at WTP of $80,000/QALY. It seems that treating patients at low risk may be 
beneficial, although it is counterintuitive that interventions in clinical practice are usually 
aiming for high-risk or high-cost patients. It is possible that MCI patients at high risk are 
close to be clinically diagnosed of AD and the treatment with higher effectiveness would 
be forgone when they covert to AD if they received treatment (with lower effectiveness) 
in the MCI stage based on the model assumption. Accordingly, for the strategy of 
targeting MCI patients at higher risk, less benefit was generated due to the treatment in 
the MCI stage and no benefit was obtained in the AD stage. 
Our decision model also focused on exploring the timing of pharmaceutical 
intervention MCI stage (MCI treatment) vs. AD stage (No MCI treatment) as this study 
was designed to investigate the potential of targeting treatments on MCI patients who 
are at risk of developing AD. Our results indicated that treating only when MCI patients 
convert to AD (no MCI treatment) was cost-effective compared to treating them upfront 
before AD (MCI treatment). The benefit of MCI treatment, conferred by way of a reduced 
progression to AD among patients with MCI only in the first 3 years, translated into an 
average gain of 3.3 months of AD-free time per patient. Compared with the treatment 
efficacy assumption made for patients with mild AD, this effect was smaller and lasted 
for a shorter period of time, which in turn resulted in the smaller expected benefit gained 
for the MCI treatment strategy. This finding was corroborated in the one-way and two-
way DSAs showing a trade-off between treatment effectiveness for MCI patients and 
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treatment effectiveness for patients with mild AD. The strategy of MCI treatment is more 
likely to be cost-effective when the RR of the treatment effectiveness for patients with 
mild AD is greater than 0.66 and no MCI treatment had a bigger region of being 
preferable than MCI treatment in the two-way DSA. Moreover, our PSA results 
presenting by the CEAC and the incremental cost-effectiveness plane suggested 
approximate 63% and 37% of chance that no MCI treatment and MCI treatment 
strategies would be cost-effective at WTP of $50,000/QALY, respectively, and 
considerable uncertainty exists.  
Although current clinical practice (i.e., treating only when MCI patients convert to 
AD) was preferred based on our CEA results, the assumption adopted in this model that 
patients received treatments either in the MCI stage or AD stage but not both resulted in 
reduced benefits. Corroborating with scenario analyses that treatment initiated in both 
MCI and AD stages would produce the greatest benefits, this implied that alternative 
treatments for patients with mild AD with the RR not greater than 0.66 and comparable 
to the current treatment on MCI patients, which allows for the continued treatments, 
would have the significant impact on the CEA results. Accordingly, it is of value to 
investigate the feasibility of treatment continuum from MCI to AD stages  
Many CEAs have assumed the cost offsets by treatment-induced delay of 
nursing home admission to reach cost-effectiveness; however, these cost offsets will be 
less substantial if differences in total AD costs (formal and informal) between residential 
settings was minimal from a societal perspective. A German study indicated that 
community-based dementia care is cost saving from the payer perspective due to 
substantially lower long-term care expenditures because of substituted unpaid 
caregiving (informal cost).75 In the case of transitions from the community to a nursing 
home, informal care is replaced by formal care.76 Thus economic expenditures for 
healthcare systems are more evident in an institutionalized setting, whereas informal 
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costs in a community-based setting place a greater economic burden on families.53 
Given that, the cost difference between residential settings contingent on the disease 
severity may be attributable only to whether the informal cost, especially in the 
community setting, was accounted for or not. In fact, studies have shown the small cost 
difference on AD patients between residential settings was found.54 With the inclusion of 
informal costs, which was estimated by replacing informal caregiving activities with 
formal care (the replacement cost approach), in the CEA and no MCI treatment resulted 
in the greater amount of AD patients staying in the mild or moderate stages than MCI 
treatment in our case, it would not be feasible for MCI treatment to reach cost-
effectiveness by means of costs offset by delaying nursing home admission.  
Healthcare costs by disease severity of AD were the key parameter in our model. 
In order to assess the cost-effectiveness of different treatment alternatives, there is a 
need for reliable and updated data on costs and health utilities for different levels 
disease severity and residential settings. However, no recent cost data of disease 
severity by residential settings is available in the US setting, which may hamper the 
evaluation of treatment strategies conducted in our model. Furthermore, the estimates of 
costs varied from study to study49-53,77, such as different measures used for disease 
severity, perspectives (societal, payers, or patients), included cost categories, as well as 
variability in care and support systems between countries.49 It is also difficult to retrieve 
the cost estimates by disease severity, residential settings, and the cost category 
(outpatients, inpatients, pharmaceuticals and non-medical, etc.) simultaneously simply 
from one study. Due to the unavailability of recent data, we used the cost estimates, 
which were conducted about twenty years ago,55 with the adjustment by inflation using 
the CPI. We further expanded the cost estimates into broad ranges in the sensitivity 
analysis and we found the findings were robust. Further studies focus on the cost 
estimates including community-based care with formal and informal service would enrich 
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the current results. 
We acknowledge several limitations in the study. First, the cost information55 
applied in this study may be outdated due to the unavailability/inapplicability of recent 
data. Changes in many social and cultural factors are very likely to influence the model 
results. With the exercise of sensitivity analyses, however, we believe that our finding is 
still justifiable. Second, we did not incorporate all possible sources of uncertainty. For 
instance, patients’ response to the pharmacological interventions was assumed to be 
consistent across different risk levels of progression from MCI to AD or among AD 
stages and also across the treatment duration. We also assumed that there is no 
residual treatment effect after treatment stops. Third, no recent treatment efficacy result 
on MCI patients is presented as the measure of the relative risk, which was used to 
estimate the treatment-associated reduction on the risk of progression to AD from MCI in 
our model (equals to multiply the RR with the transition probability). Most studies20,78,79 
reported this parameter as the effect as the point difference of cognitive tests between 
the treatment arm and the control arm, such as MMSE or the AD and associated 
disorders (ADAS), instead of the risk reduction on transition to severer stages of AD 
(presented as the RR). Better than nothing, we applied the information of the point 
difference to indirectly derive the RR of progression from the mild to moderate AD stage 
for the treatment group versus the control group. Finally, the approach in the current 
study is definitely not comparable to decision models that were structured differently, 
such as using the apoliopoprotein genetic testing combined with hypothetical treatments 
to decide the cost-effectiveness of the optimal treatment strategy on patients with MCI.33 
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3.5 Conclusion 
Still, decisions must be made, and in the absence of better evidence, appealing to 
published sources was a reasonable approach.80 Based on the current evidence, this 
study illustrates the potential for early targeted interventions for MCI patients who are at 
risk of developing AD, especially for those at low risk. Moreover, Our model and the 
findings from our analyses could be used to guide further research evaluating the cost-
effectiveness of other biomarkers used to target MCI treatment on MCI patients at 
increased risk of developing dementia. 
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Table 3.1 Parameter inputs for the state-transition Markov model. 
Parameter Mean 95% CI Distribution Source 
Annual probability of progression from MCI to AD by CSF biomarker score 27 
  low-risk group 0.064 0.01-0.16 Beta(2.46, 35.93) 
   intermediate-risk group 0.108 0.03-0.22 Beta(4.05, 33.48) 
   high-risk group 0.244 0.17-0.33 Beta(27.89, 86.40) 
 Annual transition probabilitya 
   
24,30 
  Stage to stage (AD) 
        mild to moderate 0.167 0.156-0.178 Beta(690.43, 3443.86) 
     mild to severe 0.014 0.010-0.018 Beta(59.63, 4199.86) 
     moderate to severe 0.299 0.286-0.312 Beta(1355.02, 3176.83) 
   Community to nursing home 
        mild AD 0.012 0-0.028 Beta(2.27, 186.70) 
     moderate AD 0.034 0-0.069 Beta(3.57, 101.46) 
     severe AD 0.066 0.005-0.128 Beta(3.74, 52.91) 
 Excess mortality due to AD  
    (additive effect) 0.11   
  
44,45 
Treatment effectiveness (RR)    
   MCI patients 0.84 0.70-1.00 Lognormal(-0.17, 0.096) 20 
  AD patients   ) 
35 
    mild to moderate 0.58 0.35-0.76 Lognormal(-0.55, 0.198)  
    moderate to severe 0.95 0.64-1.41 Lognormal(-0.05, 0.114)  
Treatment harm    
   Annual prob. of AE (control) 0.23 0.2-0.26 Beta(173.78, 581.77) 38 
  AEs in MCI (RR) 1.09 1.02-0.16 Lognormal(0.086, 0.02) 20 
  AEs in AD (RR) 2.51 2.14-2.95 Lognormal(0.92, 0.08) 37 
  Withdrawal due to AEb 0.19 0.14-0.24 Beta(41.67, 181.76) 37 
  Withdrawal due to non-AE 0.049 0.037-0.063 Beta(52.37, 1016.4) Assumed 
Health utility     
  MCI 0.73 0.58-0.88 Beta(23.86, 8.82) 33,41 
  AD     
    Mild     
      community 0.68 0.54-0.82 Beta(28.34, 13.34)  
      nursing home 0.71 0.57-0.85 Beta (27.97, 11.42)  
    Moderate     
      community 0.54 0.43-0.65 Beta(42.08, 35.85)  
      nursing home 0.48 0.37-0.59 Beta(37.59, 40.72)  
    Severe     
      community 0.37 0.29-0.45 Beta(67.3, 114.6)  
      nursing home 0.31 0.24-0.38 Beta(51.72, 115.11)  
  AEc  0.99 0.988-0.991 Beta(9800, 99) Assumed,43 
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Table 3.1 Continued. 
Parameter Mean 95% CI Distribution Source 
Cost ($, per person-year) 
     MCI 7,744 3,872-11,617 Gamma(15.36, 0.0020) 65 
  Formald 
   
55 
    Mild AD 
          community 9,104 4,552-13,657 Gamma(15.36, 0.0017) 
       nursing home 49,371 24,685-74,056 Gamma(15.37, 3.11) 
     Moderate AD 
          community 13,452 6,726-20,178 Gamma(15.36, 0.0011) 
       nursing home 53,736 26,868-80,604 Gamma(15.37, 2.86) 
     Severe AD 
          community 20,276 10,138-30,414 Gamma(15.37, 7.58) 
       nursing home 57,584 28,792-86,377 Gamma(15.37, 2.67) 
   Informale  
   
55 
    Mild AD 
          community 11,528 5,764-17,291 Gamma(15.36, 0.0013) 
       nursing home 1,229 615-1,844 Gamma(15.32, 0.0125) 
     Moderate AD 
          community 19,955 9,978-29,933 Gamma(15.36, 7.70) 
         nursing home 944 472-1,416 Gamma(15.34, 0.0163) 
     Severe AD 
          community 20,115 10,058-30,173 Gamma(15.37, 7.64) 
       nursing home 998 499-1,497 Gamma(15.32, 0.0153) 
   Drug (donepezil) 2,844 1,422-4,266 Gamma(15.35, 0.0054)) AWP,66 
  Office visit due to   
    treatment (per time) 81 41-122 Gamma(14.88, 0.1837) 
31 
  CSF biomarker testing  
    (per person) 315 158-473 Gamma(15.50, 0.0492) 
67 
aWe obtained the combined stage and nursing home transition probabilities by multiplying stage-
to-stage and stage-to-nursing home transitions.  
bAnnual probability derived from 6-month data by the exponential function (0.19=1-exp[-
0.1032*2]). 
cIncorporated as disutility due to the treatment 
d, eEstimates from published studies. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; RR, relative risk; AE, 
adverse event; AWP, average wholesale price; Com, community; NH, nursing home; CI, 
confidence interval. 
 
   
 96 
Table 3.2 Base-case results (per patient) for CSF biomarker testing and treatment on 
patients with MCl.* 
Strategy§ Cost ($) QALYs ICER ($/QALY)¶ 
Treat high or intermediate 265,211 7.487 - 
Treat high 265,445 7.499 Weakly dominated 
MCI treatment 265,665 7.515 16,500 
No MCI treatment 270,609 7.683 29,400 
*If MCI patients received treatment, no treatment was provided when they convert to AD. 
§MCI treatment stands for treating all MCI patients but treatment stops when they convert to AD, 
treat high was treating MCI patients at high risk, treat high or intermediate was treating MCI 
patients at high risk or intermediate risk, and no MCI treatment was treating only when MCI 
patients convert to AD (based on clinical expert opinion). 
¶The value was rounded to the nearest $100. 
Abbreviation: CSF, cerebrospinal fluid; MCI, mild cognitive impairment; AD, Alzheimer’s disease; 
ICER, incremental cost-effectiveness ratio.   
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Table 3.3 Cost-effectiveness results of allowing treatments in both MCI and AD stages 
(best-case scenario).* 
Strategy§ Cost ($) QALYs ICER ($/QALY)¶ 
No MCI treatment 270,609 7.683 - 
Treat high 272,662 7.748 Weakly dominated 
Treat high or intermediate 274,012 7.793 Weakly dominated 
MCI treatment 275,579 7.860 28,100 
§MCI treatment stands for treating all MCI patients, treat high was treating MCI patients at high 
risk, treat high or intermediate was treating MCI patients at high risk or intermediate risk, and no 
MCI treatment was that treat only when MCI patients convert to AD (based on clinical expert 
opinion). 
¶The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; AD, Alzheimer’s disease; ICER, incremental cost-
effectiveness ratio.
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Table 3.4 ICERs and QALYs decomposition of treatment scenarios by disease severity. 
Scenario* Costs ($) QALYs ICER ($/QALY)¶ QALYs decomposition MCI Mild AD Moderate AD Severe AD 
Treat neither 259,357 7.292 - 3.602 2.181 0.715 0.794 
MCI treatment 265,665 7.515 28,300 3.873 2.159 0.705 0.777 
No MCI treatment 270,609 7.683 Weakly dominated 3.602 2.759 0.632 0.690 
Treat both 275,579 7.860 28,700 3.873 2.670 0.631 0.685 
*Treat neither: no treatment in the either MCI or AD stages; MCI treatment: treat all MCI patients but treatment stops when they convert to AD; No 
MCI treatment: treat patients only when they convert to AD; treat both: treat patients in both MCI and AD stages. 
¶The value was rounded to the nearest $100. 
Abbreviation: QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; DOM, dominated; MCI, mild cognitive impairment; AD, 
Alzheimer’s disease. 
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Figure 3.1 Schematic diagram of CSF biomarker testing and subsequent treatments on patients with MCI. CSF, cerebrospinal fluid; 
MCI, mild cognitive impairment; AD, Alzheimer’s disease; Rx, treat; NH, nursing home. 
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Figure 3.2 Distribution of the weighted (health utility) AD-free life months gained with 
MCI treatment compared to no MCI treatment based on PSA 10,000 iterations. 
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Figure 3.3 One-way sensitivity analysis tornado diagram. The variables were sorted by 
their importance. The longer bars indicate parameters are the most important 
parameters. AD, Alzheimer’s disease; MCI, mild cognitive impairment; ICERs, 
incremental cost-effectiveness ratios; RR, relative risk. 
 
  
   
 102 
 
Figure 3.4 Cost-effectiveness acceptability curve showing the probability that each 
strategy is cost-effective at various willingness to pay (WTP) thresholds. QALYs: quality-
adjusted life years; WTP: willingness to pay. 
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Appendix 3.A Evidence table of input parameters in the model, adapted from Braithwaite et al.' study.29  
      Strength of evidence 
Parameter  Data Source  Reference Study designa 
internal 
validityb  
external 
validityc 
Probability (annual)      
  Mortality rate in absence of AD Observational; life tables 46 1 good low 
  Mortality rate attributable to AD Observational (systematic review); 1 study in similar population 
44 2-2 good high 
  Risk of progression to AD from MCI by CSF  
    biomarker levels Observational (cohort); ADNI (N=195) 
27 1 fair low 
  Risk of disease progression among AD stage Observational (NACC-UDS, CERAD); 2 study in similar population 
24,30 1 fair low 
  Probability of moving to nursing home  
    conditional on disease stage 
Observational (NACC-UDS, cohort); 1 study in similar 
population 
24 1 fair low 
  Risk of AEs due to treatment (MCI &AD) Observational (systematic review); 3 studies in similar population 
38 1 poor low 
  Probability of withdrawal due to AE Observational (systematic review); 13 studies in similar population 
37 1 good low 
Relative risk      
  ChEls efficacy on MCI patients Observational (systematic review); 4 studies in similar population 
20 1 good low 
  Donepezil efficacy on AD patients RCT (2 years); 1 study in similar population 35 1 low low 
  AEs associated with ChEls (MCI) Observational (systematic review); 5studies in similar population 
20 1 good low 
  AEs associated with ChEls (AD) Observational (systematic review); 13 studies in similar population 
37 1 good low 
Cost (annual)      
  CSF biomarker testing Observational; Centers for Medicare & Medicaid Services 67 1 good low 
  Donepezil Observational  1 good low 
  Other costs related to the treatment Observational; 1 study in dissimilar population 31 1 fair low 
  AD costs (formal and informal; community   
    and nursing home) Observational; 1 study in similar population 
55 1 fair low 
  MCI direct costs Observational; 1 study in similar population but conducted in Germany 
65 1 poor low 
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Appendix 3.A Continued.  
   Strength of evidence 
Parameter  Data Source  Reference Study designa 
internal 
validityb 
external 
validityc 
Utility      
  MCI Observational; 1 study in similar population 41 1 fair low 
  AD (mild, moderate, and severe) by residential    
    setting (community or nursing home) Observational; 1 study in similar population
 41 1 fair low 
  AE Observational; 1 study in dissimilar population 43 1 poor low 
Donepezil effect duration Observational (systematic review); 3 studies in similar population 
20 1 good low 
aObservational studies qualify as level 1 if they are used to estimate a parameter that cannot be determined experimentally (for example, mortality rate due to age-
,sex-, and race-related causes). 
bInternal validity is the degree to which the study provides valid evidence for the population and setting in which it was conducted.81 
cExternal validity is the extent to which the evidence is relevant and generalizable to the population and conditions of typical primary care practice. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; CSF, cerebrospinal fluid; AEs, adverse events; ChEls, cholinesterase inhibitors; ADNI, 
Alzheimer’s disease neuroimaging initiative; NACC-UDS, uniform data set of the national Alzheimer coordinating center; CERAD, Consortium to Establish a 
Registry for Alzheimer’s disease; RCT, randomized clinical trial. 
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Appendix 3.B Annual transition probabilities (combined stage and nursing home transitions) between disease severity and 
residential settings, adapted from Spackman et al.’s study.*,24 
  Time (t+1) Time (t+1) 
Time (t) Mild/Com Mild/NH Mod/Com Mod/NH Sev/Com Sev/NH Institutionalization 
Mild/Com 0.809 0.010 0.165 0.002 0.014 0.0002 0.012 
Mild/NH 
 
0.819 
 
0.167 
 
0.014 
 Mod/Com 
  
0.677 0.024 0.289 0.010 0.034 
Mod/NH 
   
0.701 
 
0.299 
 Sev/Com 
    
0.934 0.066 0.066 
Sev/NH           1   
*The table presents the combined stage and nursing home transition matrix, obtained by multiplying stage-to-stage and stage-to-nursing home 
transitions for each possible combination of disease severity and residential settings. For example, patients who begin in the mild/community state 
have a 80.9% chance (0.819 × [1-0.012]) of remaining in that state in the following year. These combined transition probabilities were computed 
conditional on being alive in the beginning of the following year.  
Abbreviation: Com, community; NH: nursing home; Mod, moderate; Sev, severe. 
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Appendix 3.C Summary of previous meta-analyses on treatment efficacy of the use of cholinesterase inhibitors in patients with mild 
cognitive impairment. 
Author, 
Year Interventions 
Included 
Studies, N 
Total 
Subjects Measurement Treatment efficacy* Conclusion 
Sobow,21¶ 
2007 ChEIs 4 3,429 CDR = 0.5 
GAL-INT-11 (2001): OR= 0.7 (0.5-1) [galantamine] 
GAL-INT-18 (2001): OR= 0.8 (0.6-1.1) [galantamine] 
InDDEX (1999): OR= 0.8 (0.6-1.1) [rivastigmine] 
Petersen (2005): OR= 0.8 (0.5-1.2) [donepezil] 
Overall: OR= 0.8 (0.6-0.9) 
The use of ChEIs 
resulted in 
approximately 24% 
reduction of risk of 
conversion from MCI 
to dementia. 
Raschetti,19 
2007 ChEIs 
8 (3 primary 
publications, 5 
RCT registers) 
  
CDR=0.5 
MMSE >26 
InDDEX (1999): OR= 0.85 (0.64-1.12) 
Petersen (2005): OR= 0.84 (0.57-1.25) 
The use of ChEIs in 
MCI was not 
associated with any 
delay in the onset of 
AD. 
Diniz,17¶ 
2009 ChEIs 4 3,574 
CDR = 0.5 or 
MMSE = 24-
30 
Winblad 1 (2008): RR= 0.60 (0.43 – 0.83) [galantamine] 
Winblad 2 (2008):RR=0.72 (0.55 – 0.95)  [galantamine] 
Feldman (2007): RR=0.81 (0.63 – 1.04) [rivastigmine] 
Petersen (2005): RR= 0.88 (0.66 - 1.18) [donepezil] 
Overall: RR= 0.75 (0.66-0.8) 
The long-term use of 
ChEIs in subjects 
with MCI may 
attenuate the risk of 
progression to 
AD/dementia. 
Birk (CR),18 
2010 Donepezil 3 782 MMSE > 23 
1st study: MD (ADAD-Cog)= 1.9 (0.51-3.29) at week 24 
Thal (1999): OR= 0.39 (0.21-0.72) at yr1; OR=0.84 
(0.57-1.25) at yr3 
There is no evidence 
to support the use of 
donepezil for 
patients with MCI. 
Russ 
(CR),20 
2012 
ChEIs 9 5,149 
CDR = 0.5 or 
MMSE = 24-
30  
Year 1: RR=0.69 (0.47-1) [Petersen 2005; Winblad 
study 1 & 2 (2008)] 
Year 2: RR=0.67 (0.55-0.83) [Winblad study 1 & 2 
(2008)] 
Year 3: RR=0.84 (0.7-1.02) [Petersen 2005; Fieldman 
2007] 
There is very little 
evidence that ChEIs 
affect progression to 
dementia or 
cognitive test scores 
in MCI. 
*95 % confidence interval was included in parenthesis. 
¶included same RCTs. 
Abbreviation: CR, Cochrane reviews; ChEls, cholinesterase inhibitors; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination; 
OR, odd ratio; RR, relative ratio; MD, mean difference. 
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Appendix 3.D Discounted quality-adjusted life years (QALYs) (weighted time) by 
disease severity (MCI, mild, moderate and severe AD) and residential settings 
(community and nursing home). 
 
We decomposed the total QALYs (with a discount rate of 3% per year) generated by 
each strategy by different disease severity and residential settings. Treating all MCI 
patients but treatment stops when they convert to AD (MCI treatment) demonstrated the 
greatest gain of AD-free life years but a relatively shorter quality-adjusted time spent in 
the mild AD/community state, whereas treating only when MCI patients convert to AD 
(MCI treatment) exhibited the longest time in the mild AD/community state. The 
difference of QALYs among each treatment strategy seemingly represented the trade-off 
of weighted time (by health utility and discount rate) spent between the MCI state and 
mild AD/community state. Admittedly, the amount of time spent in terms of the disease 
severity regardless of residential settings (assumed that care components were not 
varied by where patients dwelled) appears to drive the difference of costs incurred by 
each health state (Markov state) between treatment strategies because it is believed that 
healthcare costs are positively associated with disease severity. 
 
AD, Alzheimer’s disease; QALYs, quality-adjusted life years; MCI, mild cognitive 
impairment; Com, community; NH, nursing home. 
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Appendix 3.E Discounted lifetime costs accumulated of strategies by disease severity 
(MCI, mild, moderate and severe AD) and residential settings (community and nursing 
home). 
As expected, the cost acquired in each health state (Markov state) defined by disease 
severity and residential setting of each strategy was associated with QALYs 
accumulated in that state. The cost incurred for patients with mild AD living in the 
community was inversely related to the cost for patients with severe AD living in the 
community conditional on the proportion of MCI patients received treatment before they 
convert to AD. Specifically, with more MCI patients received treatment, the less cost 
accrued in the mild AD/community state but more in the MCI and severe AD/community 
states. Across all health states, costs of medication for MCI or AD patients constituted a 
very small proportion of the total amount of costs; the costs of pharmaceuticals 
accounted for 3-4% of total costs across different treatment strategies.  
 
AD, Alzheimer’s disease; MCI, mild cognitive impairment; Com, community; NH, nursing 
home. Discount rate was 3% per year. 
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Appendix 3.F One-way deterministic sensitivity analysis of no MCI treatment versus 
MCI treatment on the treatment effectiveness for MCI patients.* 
Treatment effectiveness 
for MCI patients (RR) ∆Cost($) ∆QALY 
ICER 
($/QALY)† Optimal strategy 
0.76 7,334 0.126 58,100 MCI treatment 
0.77§ 7,102 0.134 53,000 MCI treatment 
0.78 6,872 0.142 48,500 No MCI treatment 
0.79 6,642 0.149 44,500 No MCI treatment 
0.80 6,413 0.157 40,900 No MCI treatment 
0.81 6,185 0.165 37,600 No MCI treatment 
0.82 5,958 0.172 34,600 No MCI treatment 
0.83 5,732 0.180 31,900 No MCI treatment 
0.84¶ 5,506 0.187 29,400 No MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER is less than $50,000/QALY. 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; QALY, quality-adjusted life year; RR, relative risk; 
ICER, incremental cost-effectiveness ratio. 
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Appendix 3.G One-way deterministic sensitivity analysis of no MCI treatment versus 
MCI treatment on the treatment effectiveness for patients with mild AD.* 
Treatment effectiveness for 
patients with mild AD (RR) ∆Cost($) ∆QALY 
ICER 
($/QALY)† Optimal strategy 
0.58¶ 5,506 0.187 29,400 No MCI treatment 
0.59 5,466 0.176 31,100 No MCI treatment  
0.60 5,425 0.165 33,000 No MCI treatment 
0.61 5,384 0.153 35,100 No MCI treatment 
0.62 5,343 0.142 37,500 No MCI treatment 
0.63 5,303 0.132 40,300 No MCI treatment 
0.64 5,262 0.121 43,600 No MCI treatment 
0.65 5,222 0.110 47,400 No MCI treatment 
0.66§ 5,181 0.099 52,100 MCI treatment 
0.67 5,141 0.089 57,800 MCI treatment 
0.68 5,101 0.079 64,900 MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER is less than $50,000/QALY. 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; RR, relative risk; ICER, incremental cost-effectiveness ratio. 
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Appendix 3.H One-way deterministic sensitivity analysis of no MCI treatment versus 
MCI treatment on the excess mortality rate due to AD.* 
Excess mortality 
due to AD ∆Cost($) ∆QALY ICER($/QALY)
† Optimal strategy 
0.11¶ 5,506 0.187 29,400 No MCI treatment 
0.13 6,875 0.198 34,800 No MCI treatment 
0.15 8,016 0.207 38,800 No MCI treatment 
0.17 8,979 0.214 41,900 No MCI treatment 
0.19 9,799 0.221 44,300 No MCI treatment 
0.21 10,504 0.227 46,300 No MCI treatment 
0.23 11,115 0.232 47,900 No MCI treatment 
0.25 11,650 0.237 49,200 No MCI treatment 
0.27§ 12,121 0.241 50,300 MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER ratio is less than $50,000/QALY. 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; ICER, incremental cost-effectiveness ratio. 
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Appendix 3.I One-way deterministic sensitivity analysis of cost-effectiveness results on 
the risk of progression from MCI to AD.* 
Multiplier of risk on the 
progression to AD‡ ∆Cost($) ∆QALY ICER($/QALY)
† Optimal strategy 
0.1 11,395 0.484 23,500 MCI treatment 
0.2 7,642 0.302 25,300 MCI treatment 
0.3 4,688 0.174 27,000 MCI treatment 
0.4 2,326 0.080 29,100 MCI treatment 
0.5§ 404 0.009 46,700 MCI treatment 
0.6 1,186 0.047 25,100 No MCI treatment 
0.7 2,523 0.092 27,400 No MCI treatment 
0.8 3,663 0.129 28,300 No MCI treatment 
0.9 4,647 0.161 29,000 No MCI treatment 
1.0¶ 5,506 0.187 29,400 No MCI treatment 
1.1 6,264 0.210 29,800 No MCI treatment 
*The ICER was calculated of MCI treatment versus no MCI treatment when the multiplier was < 
0.6 (MCI treatment is cost-effective if an ICER is less than $50,000/QALY), whereas it was 
calculated of no MCI treatment versus MCI treatment when the multiplier was ≥ 0.6 (no MCI 
treatment strategy is cost-effective if an ICER is less than $50,000/QALY). 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100.  
‡We used the multiplier to conduct the sensitivity analysis on the risk of progression from MCI to 
AD. For example, the risk of MCI patients with high-risk was 0.244 × 0.6 =0.146 when the 
multiplier is 0.6. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; ICER, incremental cost-effectiveness ratio. 
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Appendix 3.J One-way deterministic sensitivity analysis of no MCI treatment versus 
MCI treatment on the treatment effect duration on MCI patients.* 
Treatment effect 
duration ∆Cost($) ∆QALY 
ICER 
($/QALY)† Optimal strategy 
3¶ 5,506 0.187 29,400 No MCI treatment 
4 4,258 0.143 29,700 No MCI treatment 
5 3,249 0.108 30,100 No MCI treatment 
6 2,430 0.079 30,600 No MCI treatment 
7 1,760 0.056 31,400 No MCI treatment 
8 1,211 0.037 32,700 No MCI treatment 
9 759 0.021 35,700 No MCI treatment 
10 386 0.008 46,300 No MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER is less than $50,000/QALY. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; QALY, quality-adjusted life year; ICER, incremental 
cost-effectiveness ratio. 
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Appendix 3.K One-way deterministic sensitivity analysis of no MCI treatment versus 
MCI treatment on the annual cost of medication.* 
Annual costs of 
medication ($)  ∆Cost($) ∆QALY ICER($/QALY)
† Optimal strategy 
100 1,867 0.187 10,000 No MCI treatment 
1,000 3,061 0.187 16,400 No MCI treatment 
1,500 3,724 0.187 19,900 No MCI treatment 
2,000 4,387 0.187 23,400 No MCI treatment 
2,500 5,050 0.187 27,000 No MCI treatment 
2,844¶ 5,506 0.187 29,400 No MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER is less than $50,000/QALY. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; QALY, quality-adjusted life year; ICER, incremental 
cost-effectiveness ratio. 
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Appendix 3.LOne-way deterministic sensitivity analysis of no MCI treatment versus MCI 
treatment on the time horizon of the analysis.* 
Time horizon (year) ∆Cost($) ∆QALY ICER($/QALY† Optimal strategy 
10 416 0.045 9,300 No MCI treatment 
15 1,779 0.118 15,100 No MCI treatment 
20 3,564 0.170 21,000 No MCI treatment 
25 4,919 0.190 25,800 No MCI treatment 
30 5,451 0.192 28,400 No MCI treatment 
35¶ 5,506 0.187 29,400 No MCI treatment 
*No MCI treatment strategy is cost-effective if an ICER is less than $50,000/QALY. 
¶The value used in the base-case analysis.  
†The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; QALY, quality-adjusted life year; ICER, incremental 
cost-effectiveness ratio. 
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Appendix 3.M Optimal strategy based on the two-way deterministic sensitivity analysis of treatment effectiveness for MCI patients 
versus treatment effectiveness for patients mild AD.* 
Treatment effectiveness 
for MCI patients (RR) 
Treatment effectiveness for patients with mild AD (RR) 
0.59 0.6 0.61 0.62 0.63 0.64 0.65 0.66 
0.75 Treat Treat Treat Treat Treat Treat Treat Treat 
0.76 Treat Treat Treat Treat Treat Treat Treat Treat 
0.77 Treat Treat Treat Treat Treat Treat Treat Treat 
0.78 Treat Treat Treat Treat Treat Treat Treat Treat 
0.79 No treat Treat Treat Treat Treat Treat Treat Treat 
0.80 No treat No treat Treat Treat Treat Treat Treat Treat 
0.81 No treat No treat No treat Treat Treat Treat Treat Treat 
0.82 No treat No treat No treat No treat No treat Treat Treat Treat 
0.83 No treat No treat No treat No treat No treat No treat Treat Treat 
0.84¶ No treat No treat No treat No treat No treat No treat No treat Treat 
*No MCI treatment strategy is cost-effective if an incremental cost effectiveness ratio is less than $50,000/QALY. 
¶The value used in the base-case analysis. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted life year; RR, relative risk; No treat, the no MCI 
treatment strategy; treat, the MCI treatment strategy. 
 
  117 
Appendix 3.N Optimal strategy based on the two-way deterministic sensitivity analysis 
of the treatment effect duration vs. treatment effectiveness for patients with mild AD.* 
Treatment effect 
duration on MCI 
patients 
Treatment effectiveness for patients with mild AD (RR) 
0.58¶ 0.59 0.6 0.61 0.62 0.63 
3¶ No treat No treat No treat No treat No treat No treat 
4 No treat No treat No treat No treat No treat No treat 
5 No treat No treat No treat No treat No treat Treat 
6 No treat No treat No treat Treat Treat Treat 
7 No treat No treat Treat Treat Treat Treat 
8 No treat No treat Treat Treat Treat Treat 
9 No treat Treat Treat Treat Treat Treat 
10 No treat Treat Treat Treat Treat Treat 
*No MCI treatment strategy is cost-effective if an incremental cost effectiveness ratio is less than 
$50,000/QALY. 
¶The value used in the base-case analysis. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; RR, relative risk; ICER, incremental cost-effectiveness ratio; No treat, the no MCI 
treatment strategy; treat, the MCI treatment strategy. 
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Appendix 3.O Monte Carlo simulation (n=10,000) results on the incremental cost-
effectiveness plane. The diagonal dashed-line represents a cost per QALY gained of 
$50,000. 
 
According to the theory of cost-effective resource allocation,82 the strategy of no MCI 
treatments is preferred for all points below the dashed line in the northeast quadrant or 
all points above the dashed line in the southwest quadrant. The No MCI treatment 
strategy is also preferred for all points in the southeast quadrant, while treating all MCI 
patients (MCI treatment) is preferred for all points in the northwest quadrant, all points 
below the dashed line in the southwest quadrant or all points above the dashed line in 
the northeast quadrant. 
 
 
MCI, mild cognitive impairment; QALYs, quality-adjusted life years. 
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Appendix 3.P Cost-effectiveness acceptability curve of the best-case scenario that treat 
AD patients regardless if they received the treatment in the MCI stage or not. 
 
AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALYs: quality-adjusted life years; 
WTP: willingness to pay. 
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Appendix 3.Q One-way deterministic sensitivity analysis of MCI treatment versus no 
MCI treatment on the treatment effectiveness for MCI patients in the best-case 
scenario.* 
Treatment effectiveness 
for MCI patients (RR) ∆Cost($) ∆QALY 
ICER($/QAL
Y)† Optimal strategy 
0.84¶ 4,566 0.163 28,100 MCI treatment 
0.85 4,820 0.156 30,900 MCI treatment 
0.86 5,072 0.150 33,900 MCI treatment 
0.87 5,324 0.143 37,200 MCI treatment 
0.88 5,575 0.136 40,900 MCI treatment 
0.89 5,825 0.130 44,800 MCI treatment 
0.90 6,074 0.123 49,200 MCI treatment 
0.91§ 6,322 0.117 54,000 No MCI treatment 
0.92 6,569 0.111 59,400 No MCI treatment 
0.93 6,815 0.104 65,400 No MCI treatment 
0.94 7,060 0.098 72,200 No MCI treatment 
*The best-case scenario means treating patients both in the MCI and AD stages. MCI treatment 
is cost-effective if an ICER is less than $50,000/QALY. 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; RR, relative risk; ICER, incremental cost-effectiveness ratio. 
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Appendix 3.R One-way deterministic sensitivity analysis of varying the parameter of the 
treatment effectiveness for patients with mild AD in the MCI treatment strategy 
compared to the fixed effectiveness for the strategy of no MCI treatment in the best-case 
scenario.* 
Treatment effectiveness 
for patients with mild AD 
(RR) 
∆Cost($) ∆QALY ICER($/QALY)† Optimal strategy 
0.58¶ 4,566 0.163 28,100 MCI treatment 
0.59 4,532 0.153 29,700 MCI treatment 
0.60 4,497 0.143 31,500 MCI treatment 
0.61 4,463 0.133 33,500 MCI treatment 
0.62 4,429 0.123 35,900 MCI treatment 
0.63 4,395 0.114 38,600 MCI treatment 
0.64 4,360 0.104 41,800 MCI treatment 
0.65 4,326 0.095 45,600 MCI treatment 
0.66§ 4,292 0.085 50,200 No MCI treatment 
0.67 4,258 0.076 55,800 No MCI treatment 
0.68 4,225 0.067 62,900 No MCI treatment 
*The best-case scenario means treating patients when they convert to AD regardless if they have 
received treatment in the MCI stage or not. MCI treatment with varying treatment effectiveness for 
patients with mild AD is cost-effective if an ICER is less than $50,000/QALY. 
§The threshold that the optimal strategy changed. 
¶The value used in the base-case analysis. 
†The value was rounded to the nearest $100. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; QALY, quality-adjusted 
life year; RR, relative risk; ICER, incremental cost-effectiveness ratio. 
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Appendix 3.S Cost-effectiveness results of including strategies of treating MCI patients 
at low risk and treating MCI patients at low or intermediate risk.* 
Strategy§ Cost ($) QALYs ICER ($/QALY)¶ 
Treat high or intermediate 265,211 7.487  
Treat high 265,445 7.499 Weakly dominated 
MCI treatment 265,665 7.515 16,500 
No MCI treatment 270,609 7.683 29,400 
Treat low or intermediate 271,460 7.699 Weakly dominated 
Treat low  271,694 7.710 39,500 
*If MCI patients received treatment, no treatment was provided when they convert to AD. 
§MCI treatment stands for treating all MCI patients, treat high was treating MCI patients at high 
risk, treat high or intermediate was treating MCI patients at high or intermediate risk, treat low 
was treating MCI patients at low risk, treat low or intermediate was treating MCI patients at low or 
intermediate risk, and no MCI treatment was no treatment on all MCI patients until they convert to 
AD (based on clinical expert opinion). 
¶The value was rounded to the nearest $100. 
Abbreviation: CSF, cerebrospinal fluid; MCI, mild cognitive impairment; QALYs, quality-adjusted 
life years; ICER, incremental cost-effectiveness ratio.   
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Appendix 3.T Two-way sensitivity analysis of treatment effectiveness for mild AD 
patients vs. treatment effectiveness on MCI patients. 
 
AD, Alzheimer’s disease; MCI, mild cognitive impairment. 
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Appendix 3.U Cost-effectiveness acceptability curve of including strategies of treating 
MCI patients at low risk and treating MCI patients at low or intermediate risk. 
 
MCI, mild cognitive impairment; QALYs, quality-adjusted life years; WTP, willingness to pay. 
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Appendix 3.V Cost-effectiveness results of allowing treatments in both MCI and AD 
stages (best-case scenario).* 
Strategy§ Cost ($) QALYs ICER ($/QALY)¶ 
No MCI treatment 270,609 7.683  
Treat high 272,662 7.748 Weakly dominated 
Treat low  272,806 7.750 Weakly dominated 
Treat high or intermediate 274,012 7.793 Weakly dominated 
Treat low or intermediate 274,156 7.794 Weakly dominated 
MCI treatment 275,579 7.860 28,100 
§MCI treatment stands for treating all MCI patients, treat high was treating MCI patients at high 
risk, treat high or intermediate was treating MCI patients at high risk or intermediate risk, and no 
MCI treatment was no treatment on all MCI patients until they convert to AD (based on clinical 
expert opinion). 
¶The value was rounded to the nearest $100. 
Abbreviation: MCI, mild cognitive impairment; AD, Alzheimer’s disease; ICER, incremental cost-
effectiveness ratio. 
  
 
Chapter 4. Value of Information Analysis to Explore the 
Uncertainty of an Early Identification Model of Alzheimer’s 
Disease 
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Brief overview 
Objective: To estimate the societal value of reducing uncertainty in a decision whether 
or not to use cerebrospinal fluid biomarker (CSF) testing to target early treatments for 
patients with mild cognitive impairment (MCI) who are at risk of developing Alzheimer’s 
disease (AD). 
Methods: We used a previously developed model that evaluated the cost-effectiveness 
of different test-and-treat strategies for MCI patients. CSF biomarker testing categorized 
patients into risk groups to target treated with cholinesterase inhibitors (ChEIs) for a 
subset of patients. We used value of information analysis (VOI) to quantify the expected 
gain from reducing parameter uncertainty associated with these test-and-treat strategies. 
We derived the expected value of perfect information (EVPI) for all input parameters or a 
single parameter (partial EVPI), as well as the corresponding expected value of 
sampling information (EVSI), and computed the optimal sample sizes for additional 
research through the expected net benefit of sampling (ENBS) for those parameters. To 
demonstrate the use of the EVSI and the ENBS to determine the optimal sample size of 
a new study, we assumed that a fixed cost of $10 million and a variable cost of $2,000 
per patient for a study collecting data on all parameters. If data on only one parameter 
was to be collected, we assumed a fixed cost of $5 million and a variable cost of $1,000 
per patient. 
Results: The total EVPI was $2,122 per patient. The parameters of treatment 
effectiveness for patients with mild AD and treatment effectiveness for MCI patients were 
most responsible for uncertainty in the decision model (partial EVPI = $1,300 and $820, 
respectively). A maximum ENBS of $29 million was reached with an optimal sample size 
of 1,700 patients for a new study to inform the parameter of treatment effectiveness on 
patients with mild AD. A study collecting data on the treatment effectiveness for MCI 
  128 
patients would have an optimal sample size of 3,000 patients and a maximized ENBS of 
$ 7 million. 
Conclusions: Given our estimates of study costs, the efficient study design for the use 
of CSF biomarker testing on MCI patients for targeted early treatment involves a trial of 
1,700 patients on treatment effectiveness for patients with mild AD and a trial of 3,000 
patients on treatment effectiveness for MCI patients, both using ChEIs. VOI analysis 
provides value-based information in additional to the typical sensitivity analysis 
(deterministic or probabilistic) to examine the importance of input parameters.   
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4.1 Introduction 
Decision analysis provides a method to systematically incorporate current evidence in 
order to inform healthcare decisions such that patients’ expected outcomes are 
maximized. The results of a decision analysis can inform the best course of action if the 
decision were to be made today. However, we know that even the best available 
evidence is associated with various degrees of uncertainty, which in turn can have 
implications on the degree of certainty one has with respect to healthcare decisions.1 
While all decisions are associated with various levels of uncertainty, it is important to 
keep in mind that decisions still have to be made (i.e., “not making a decision” is a 
decision).  
The evaluation of uncertainty in the field of medical decision making is receiving 
increasing attention.2-4 In general, decision makers should prefer the alternative that 
maximizes the expected value of outcome of interests in a decision problem. The 
outcome of interest could be life expectancy, avoidable hospital admission averted, net 
health benefits and so on, depending on the perspective of the decision maker. 
Increased uncertainty surrounding a particular problem increases the concern that the 
decision maker is making the right decision and also influences their perception of the 
necessity for further research.5 Decisions based on existing information are associated 
with uncertainty and thus there is always a chance that a wrong decision will be made. 
This, in turn, may have health- and cost-related consequences (opportunity loss from 
making a wrong decision). In order to gain more confidence in making the decision, 
conduction additional research to obtain more information6 about the key components 
that are influential to the decision-making process is considered. The necessity to 
conduct further research is usually greater when the chosen decision is sensitive to 
those key components. Consequently, the question is whether or not the decision should 
be made based on current information or whether or not it is worth investing in additional 
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data collecting exercise to reduce uncertainty before revisiting the decision.7 An 
approach to ascertain this question is to quantify the expected value gained from 
reducing uncertainty in a decision problem through additional research8 and then 
evaluate whether it is justified by means of value of information (VOI) analysis.  
VOI analysis is a quantitative method which can be used to estimate the cost-
effectiveness of a new proposed research project.7 The expected value gained from 
additional research is equal to the expected loss (i.e., poorer patient outcomes) from 
making a wrong decision due to uncertainty of input parameters in a decision model.6 
This expected value is compared with the expected cost of a proposed research project 
to decide the cost-effectiveness of additional research. If the expected value exceeds 
the (expected) cost the research project should be undertaken.  
In the decision analysis whether or not to use cerebrospinal fluid (CSF) 
biomarker testing on patients with mild cognitive impairment (MCI) for early targeted 
treatments to delay the progression of Alzheimer’s disease (AD), the findings were 
inconclusive. Using a cost-effectiveness analysis (CEA), in a previous study (Paper 2),9 
we assessed the six treatment strategies where CSF biomarker information (risk levels 
of developing AD) was used to decide the treatment threshold for a hypothetical cohort 
of 65-year-old patients with MCI, which is considered as the prodromal stage of AD. We 
found CSF biomarker testing seems to add value to the guidance of targeting earlier 
pharmacological intervention on patients with MCI, especially for those at low risk, but 
parameter uncertainty on treatment effectiveness for MCI and AD patients is substantial 
in this case. Before we reach the conclusion for the optimal treatment strategy for MCI 
patients, VOI analysis provides value-based information for either choosing the strategy 
based on the current evidence or revisiting the problem after more information is 
collected. Although previous studies6 have conducted VOI analysis on the treatment 
efficacy of donepezil for AD patients, they did not extend the decision model to 
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incorporate the prodromal stage of AD and the CSF biomarker information was 
unavailable to categorize MCI patients into different risk levels of developing AD so that 
was not accounted for in their study. Thus, the objective of our study was to evaluate the 
societal value of reducing uncertainty in the early-identification decision model of AD, 
which was constructed to answer the question whether or not to use CSF biomarker 
testing to target early treatments for MCI patients in Paper 2. We conducted a VOI 
analysis to explore uncertainty associated with the input parameters by estimating the 
value of additional information to better inform the estimates of the existing input 
parameters used in this decision model. We also extended the scope of this study to 
include structural uncertainty. 
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4.2 Methods 
A detailed description of the original decision model can be found elsewhere (Paper 2).9 
Briefly, we developed a state-transition Markov model to project discounted lifetime 
quality-adjusted life years (QALYs) and costs and then conducted a CEA to evaluate the 
treatment strategies with and without CSF biomarker testing involved for MCI patients 
who are at risk of developing AD (Appendix 4.A). The treatment strategies (test-treat 
strategies) including the test results, which was used to stratify MCI patients into risk 
groups- low, intermediate and high- to decide the treatment strategy, were strategies of: 
1) treating MCI patients at low risk (treat low), 2) treating MCI patients at low or 
intermediate risk (treat low or intermediate), 3) treating MCI patients at high risk (treat 
high), and 4) treating MCI patients at high or intermediate risk (treat high or 
intermediate). We also evaluated strategies where no biomarker information was 
obtained (i.e., no testing strategies); 1) no test and treat only when MCI patients convert 
to AD (no MCI treatment) and 2) no test and treat all MCI patients (MCI treatment). We 
assumed that if patients received treatment in the MCI stage, they would not be eligible 
for treatment when they converted to AD based on clinical expert opinion. In this study, 
we conducted VOI analysis to estimate the value of reducing uncertainty surrounding 
input parameters in this decision model to inform additional research decisions, whereas 
results of CEA from the decision model are used to inform the treatment decision. 
 
4.2.1 Cost-effectiveness analysis 
We adopted the net benefit approach to present the results of CEA. Costs and effects 
(QALYs) were combined into a single outcome:10 net monetary benefit (NMB) = effect × 
willingness to pay (WTP) – cost or net health benefit (NHB) = effect – cost/WTP. We 
used a societal WTP threshold at various levels (up to $100,000/QALY). The strategy 
with the maximum net benefit is considered the optimal strategy. In this study, we used 
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the measure of NMB to present the results of a VOI analysis because it quantifies the 
expected value of reducing parameter uncertainty in a decision model through additional 
research. Otherwise, the results were presented as NHB. The principle is similar 
whether the benefit is cash, utility or some other metric. 
We presented the CEA result from a probabilistic analysis to account for the 
nonlinear feature of Markov model used in the original model, in which the input 
parameters should ideally be modeled with probability distributions instead of point 
estimates. Because a model outcome, f(x), when estimated by an approach of a Markov 
model, is a nonlinear function of uncertain model parameters (x). Accordingly, the 
expected value of f(x) is not equal to the function of the expected value of x.11,12  
 
4.2.2 Uncertainty analysis 
A number of types of uncertainty are relevant to the assessment of the cost-
effectiveness of a particular intervention question, including the input parameters, the 
statistical methods used to estimate the input parameters, the structure of decision-
analytical model, and the perspective to a decision question (societal or payer).13,14 In 
this paper, I mainly focused on evaluating uncertainty relevant to input parameters in the 
decision model, including the chance of making a wrong decision and the consequence 
associated with it, and the structure of the decision model.  
 
4.2.2.1 Characterization of input parameters information 
The characterization of input parameter uncertainty is critical in CEA, particularly when 
considering the value of conducting additional research.13 The result of the base case 
CEA is affected by the mean of expected outcomes (NMB in our case), which is affected 
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by the distributions assigned to input parameters, whereas a VOI analysis depends on 
the distribution of expected outcomes. 
The characterization of uncertainty surrounding input parameters in this decision 
model is summarized in Table 4.1. We used data from a longitudinal and observational 
study- the Alzheimer’s Disease Neuroimaging Initiative (http://adni.loni.usc.edu/) to 
estimate the risk of progression from MCI to AD defined by CSF biomarker levels.15 
Treatment efficacy of cholinesterase inhibitors (ChEIs) for MCI patients was obtained 
from the results of a recent systematic review of 9 clinical control trials16 with a maximum 
3-year study period and the effect was rated as modest, whereas the efficacy for 
patients with mild or moderate AD was derived from a randomized placebo-controlled 
double-blind clinical trial (RCT).17 
The annual risk of progression from MCI to AD by CSF biomarker levels was 
characterized with beta distributions. Beta distributions are commonly used to describe 
uncertainty of probabilities because they range between 0 and 1. The mean health utility 
for each health state (Markov state) adopted in the model was characterized with beta 
distributions with 95% confidence intervals (CIs) based on the lower and upper bound 
values computed in a similar CEA study.18 Published data for formal and informal costs 
for each AD stages, separated by residential settings (community or nursing home), 
were reported as mean values (μ) only. As a result, we characterized their distribution 
with a gamma distribution (values are greater than zero and right skewed). We further 
derived the standard deviation (SD) by assuming the original cost data were normally 
distributed with 50% less or higher from the same mean as the lower bound (0.5μ) and 
upper bound (1.5μ) of the 95% CI. Thus, we computed the SD of the assigned gamma 
distribution for each specified cost parameter associated with AD stages as the mean 
divided by (2×1.96). The treatment efficacy for MCI patients was expressed as the 
relative risk (RR) multiplying with the risk of progression from MCI to AD, so we 
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characterized the RR with a lognormal distribution based on the reported mean and the 
CIs from a meta-analysis.16 On the other hand, the treatment effects for patients with 
mild or moderate AD were modeled as the RR multiplying with the probabilities of 
transitions between AD stages, such as from mild to moderate AD and mild to severe 
AD, or moderate to severe AD. Thus, it was also characterized with a lognormal 
distribution using information from an RCT.17 Withdrawal rates due to the treatment 
associated with adverse events (AEs) either for MCI patients or for AD patients were 
characterized with beta distributions with the mean and the SD based on the estimates 
from a meta-analysis.19  
The duration of treatment effect on MCI patients was fixed as constant (3 years) 
in the base case CEA because the results of a recent meta-analysis of examining ChEI 
effect on MCI patients only presented 3-year results.16 In addition, the effect duration on 
AD patients was assumed to continue until they transition to the severe stage or 
discontinue due to AEs. The parameter of treatment effect duration on AD patients was 
found to be the key parameter in a previous CEA20 that this study was adapted to, where 
the treatment effect duration on AD patients was 24 weeks in the base case analysis 
and 210 week (about 4 years) in the VOI analysis. In our study, it was calculated as 
about 5.4 years of treatment for AD patients before they transition to the severe stage 
based on the parameters applied. 
 
4.2.2.2 Probabilistic sensitivity analysis (parameter uncertainty) 
We used the sample (n=10,000), which was generated from a randomly drawn values 
for each parameter from its assigned probability distribution using a second-order Monte 
Carlo repeat sampling method, to calculate the base case CEA result, and further 
performed a probabilistic sensitivity analysis (PSA). We presented PSA results as a 
cost-effectiveness acceptability curve (CEAC),21 which shows the percentage of 
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iterations that a strategy is optimal (with the highest NHB). Because expected outcomes 
of costs and QALYs were regenerated for each strategy based on the drawn values of 
input parameters in each iteration, the output of the PSA provided distributions of costs 
and QALYS along with distributions of input parameters. We used this output to conduct 
a VOI analysis in the following section.  
 
4.2.2.3 Value of information analysis (decision uncertainty) 
VOI analysis uses Bayesian updating methods to estimate the potential benefits of 
gathering further information, through more research, to reduce the uncertainty 
surrounding a decision problem.8 The key concept in Bayesian analysis is the updating 
of a prior belief about plausible values for a input parameter with the support for likely 
values of that parameter drawn from sampled data (the distribution of which is known as 
the likelihood function) to form a posterior belief using Bayes theorem.7 The results of a 
data collection exercise (e.g., a clinical trial) are predicted based on current knowledge. 
These are combined with the current knowledge to predict the state of knowledge 
(update a degree of belief about an input parameter) after the data are collected.  
 
4.2.2.3.1 Expected value of perfect information - overall uncertainty 
In a classic decision analysis, the optimal choice between two or more strategies is the 
one with the highest expected value of the model outcome.22 The estimates of the 
expected values are made on the basis of the currently best available data, even though 
imprecise or incomplete, thus, the outcome result generated with the current evidence is 
thus referred to as the expected value given current information. The underlying 
uncertainty in the data introduces the possibility that a decision made based on the 
current information may not actually be the one with the highest expected value (i.e., it 
will be the wrong decision). Conversely, it is possible to compute the expected value of 
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outcomes given perfect information if the optimal decision were known (theoretically) 
under all possible values for input parameters. The difference between these two 
expected values (given perfect information vs. given current information) is the expected 
value of perfect information (EVPI), the upper bound of the expected value from 
reducing parameter uncertainty in a decision model and the value of collecting data 
about all input parameters in a hypothetical infinitely large study.23 
Specifically, the EVPI, as shown in Equation 1, is the difference between the 
expected value of a decision made given perfect information (the first term) about all of 
the uncertain input parameters θ, which is a vector, and a decision made given current 
information (the second term).23 The NMB is the net monetary benefit and the expected 
outcomes in our decision model and d is the strategy.  
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 = 𝐸𝐸𝜃𝜃[𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃)] −𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝐸𝐸𝜃𝜃𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃)                                  (1)  
Using a second-order Monte Carlo repeat sampling approach,11 we can rewrite Equation 
1 as follows. N stands for the number of model iterations (sampling). 
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸� = 1
𝑁𝑁
�𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝑁𝑁𝑁𝑁𝑁𝑁�𝑑𝑑,𝜃𝜃(𝑛𝑛)�𝑁𝑁
𝑛𝑛=1
− 𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑
1
𝑁𝑁
�𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃(𝑛𝑛))𝑁𝑁
𝑛𝑛=1
 
This approach is illustrated in Appendix 4.B using a simplified, two alternative strategies, 
MCI treatment and no MCI treatment, with the expected value of NMB generated for 
each one. Each iteration consists of drawing a random value for each input parameter 
from distribution assigned in the PSA. 
To determine whether additional data collection might be beneficial, the costs 
associated with conducting further studies should be compared to the population EVPI.24 
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Population EVPI places an upper bound on the value of further research for the 
population that can potential benefit from it. It is calculated by multiplying the EVPI per 
patient with the number of patients affected by the decision each year (i.e., the annual 
incidence of new MCI patients in the US) and the projected affected time horizon of the 
decision.23 For the US perspective, we estimated the annual population that could 
potentially benefit from the results of a future study to be 10% of the 162 (range, 122-
202) thousand patients with MCI who are 65-year-old using the projection of an 
incidence rate (60.4, 95%CI: 45.6-75.3 per 1,000 person-years) from the Aging, 
Demographics, and Memory Study26 along with the 2013 US census data. We assumed 
that the projected effective lifetime of this decision problem, whether or not to apply CSF 
biomarker testing on patients with MCI for early targeted treatments, is 2 years and 
varied it (2-8 years)6 in a sensitivity analysis. The computation of the affected population 
was shown as Equation 2 in which T is the effective lifetime of this decision, It is the 
estimates of incidences over this period, and r is the discount rate which was assumed 
at a rate of 3% per year.25 
 
𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 = 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 ×  ∑ 𝐼𝐼𝑡𝑡(1+𝑟𝑟)𝑡𝑡𝑇𝑇𝑡𝑡=1                                                  (2) 
 
4.2.2.3.2 Partial expected value of perfect information 
It is often of interest to estimate the EVPI for an individual parameter or sets of 
parameters (partial EVPI). Partial EVPI is often used to identify the parameters that are 
most influential (with the highest expected value) to decision uncertainty3,23,24 and as 
such can be used to guide the design and prioritization of future research to better 
inform the values of these parameters.27,28 Again, θ stands for all the uncertain 
parameters input in our decision model, and can be further divided into θi (subsets of 
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parameters of interest) and θ-i (the complement set of parameters) as shown in Equation 
3. Similarly, the NMB stands for the net monetary benefit and is the expected outcomes 
in our decision model and d is the strategy. 
𝐸𝐸𝑚𝑚𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚𝑃𝑃 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 = 𝐸𝐸𝜃𝜃𝑖𝑖[𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝐸𝐸𝜃𝜃−𝑖𝑖|𝜃𝜃𝑖𝑖𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃𝑖𝑖 , 𝜃𝜃−𝑖𝑖)] −𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝐸𝐸𝜃𝜃𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃)              (3) 
We estimated the partial EVPI for an individual parameter and sets of parameters that 
were categorized into the cost, QALY, and transition probability groups, to identify either 
an individual parameter or a set of parameters (θi) with the highest expected value 
regarding decision uncertainty.  
Again, with Monte Carlo repeat sampling methods which was used to calculate 
the EVPI, Equation 2 can be expressed as: 
𝑃𝑃𝑚𝑚𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚𝑃𝑃 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸� = 1
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�𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃𝑖𝑖(𝑘𝑘),𝐽𝐽
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(𝑘𝑘,𝑗𝑗)) −𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑 1𝑁𝑁�𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑, 𝜃𝜃(𝑛𝑛))𝑁𝑁
𝑛𝑛=1
 
In the first term, j and k stand for the number of sampling in the inner and outer loops 
defined in the Monte Carlo repeat sampling method, respectively. In order to calculate 
the expected value of the NMB based on each parameter set, the outer loop draws the 
value from the distribution of parameters of interest, whereas the inner loop draws the 
values from distributions of all the rest parameters. The second term is the same as in 
Equation 1, but N now is equal to j × k times model iterations. By sampling the 
parameter of interest in the outer loop while sampling all the rest parameters in the inner 
loop simultaneously to control the bias due to the nonlinear feature of Markov model, we 
computed the partial EVPI as the unbiased expected value of conducting additional 
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research specifically on the parameters of interest. 
Partial EVPI analyses can be computed either using one-level (the outer loop 
only)5 if a decision model come with the linear structure or using two-level (the inner and 
outer loops together) sampling algorithms.12 When a model is perfectly linear and no 
correlation exists between input parameters, the one-level sampling algorithms will 
provide estimates of the partial EVPI that are equal to the two-level sampling 
algorithms.27 In our case, nevertheless, this assumption was not fulfilled because of the 
Markov model feature. An inherent characteristic of a Markov model is the multiplication 
of matrices with transition probabilities over subsequent cycles, causing the models to 
be nonlinear.27 The total iterations for a partial EVPI analysis in our case would be j 
times k when applying two-level methods. This may become the computational 
burdensome when the number of iteration for inner and outer loops is high.29 To save 
the computational cost and resolve the possible correlations existing between 
parameters without using more complicated methods (e.g., Markov chain Monte Carlo 
[MCMC]), we adopted the nonparametric generalized additive model (GAM) proposed by 
Strong et al.30 to estimate partial EVPIs.  
Specifically, we exported the PSA results (10,000 sets) with sampled input 
parameters from their assigned distributions and the expected outcomes, expressed as 
costs and QALYs ,and fitted the model output with the GAM. We particularly focused on 
the parameters of the treatment efficacy for MCI or AD patients, the risk of progression 
to AD from MCI, health utilities, and the costs of formal and informal care.  
 
4.2.2.3.3 Expected value of sample information and the optimal sample size 
The total EVPI and the partial EVPI are relevant to evaluate the importance of overall 
uncertainty and identify key parameters responsible for decision uncertainty. However, 
they are insufficient to justify and guide further research because they are estimated 
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based on a hypothetical infinitely large sample.3  
The expected value of sample information (EVSI) is the expected benefit of 
reducing uncertainty by obtaining information from a future study, collecting information 
on all parameters, with a finite sample size.23 That is, the total EVSI for all input 
parameters or the partial EVSI for a single parameter or a set of parameters will reach a 
ceiling: the corresponding EVPI or the partial EVPI of that parameter(s), with the 
increasing sample size of a new study.31 Estimation of the total EVSI or the partial EVSI 
across a range of sample sizes can allows us to find the optimal sample size in terms of 
the expected cost of a new study for the key parameters. The key component of 
computing the EVSI is to use the Bayesian updating procedure and then the existing 
uncertainty for a single parameter or a set of parameters can be updated from a 
proposed a new study (new evidence) to form a new (updated) distribution for the input 
parameters.32 The step-by-step algorithm of Bayesian updating procedure to compute 
the partial EVSI can be found in published studies.23,32 However, to use the Bayesian 
method, we need to specify the distribution not only for the input parameters but also for 
a new study that will provide the new evidence. It can be challenging if the distribution of 
new data are not conjugate to the distribution of input parameters, where more complex 
methods (e.g., MCMC) will be needed.23,32 Thus, we used the GAM model33 mentioned 
above to estimate the total EVSI and partial EVSI (using the same parameters 
considered in partial EVPI analyses). We also estimated the partial EVSI for several sets 
of parameters to assess various study designs aimed at informing a subset of 
parameters. To compute the EVSI by the GAM model, we still had to assign a 
distribution for the new data collection based on the type of data collected. We assumed 
the binomial distribution for studies that update probabilities (e.g. the risk of progression 
to AD) because the random variable drawn from such distribution is the number of 
events (patients who have progressed from MCI to AD) in a new study. Analogously, we 
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assumed the normal, the lognormal, and the binomial distributions for studies on costs, 
the treatment efficacy, and the health utilities, respectively.  
Any effort to improve the quality of available data that costs less than the 
population EVSI, which is calculated by multiplying the EVSI per patient with the number 
of patients affected by the decision problem each year (similar to the population EVPI 
calculation), is worth pursuing.22 That is to say, comparing the population (partial) EVSI 
with the cost of additional studies that will provide new evidence for an input parameter 
allows us to determine if the additional research for that parameter is justified. For 
example, additional research of treatment efficacy either for MCI or AD patients may be 
justified if the expected value of the population (partial) EVSI exceeds the expected cost 
of that additional research. 
The expected net benefit of sampling (ENBS)3,12 as shown in Equation 4, is 
derived by subtracting the cost of a proposed new study from the population EVSI: 
𝐸𝐸𝑁𝑁𝑁𝑁𝐸𝐸(𝑃𝑃) = 𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 (𝑃𝑃) − �𝑓𝑓𝑃𝑃𝑚𝑚𝑓𝑓𝑑𝑑 𝑐𝑐𝑃𝑃𝑐𝑐𝑃𝑃 + �𝑣𝑣𝑚𝑚𝑃𝑃𝑃𝑃𝑚𝑚𝑣𝑣𝑃𝑃𝑓𝑓 𝑐𝑐𝑃𝑃𝑐𝑐𝑃𝑃 ×  (𝑃𝑃)��         (4) 
where n stands for the sample size of a new proposed study and fixed and variable 
costs are the cost of a proposed new study. If the ENBS(n) > 0 for any sample size, then 
further research is justified.34 The ENBS also provides a framework for the efficient 
design of a clinical trial. The optimal sample size n* for a proposed trial is where the 
ENBS reaches a maximum.35 At this maximum the additional benefit of one more patient 
in the study equals the additional study costs of one more patient in the study.31 To 
demonstrate the use of the EVSI and the ENBS to determine the optimal sample size for 
a hypothetical clinical trial collecting data on all parameters (total EVSI), where we 
assumed a fixed cost of $10 million and a variable cost of $2,000 per patient. In practice, 
this framework could be use to evaluate the sample size of a future study on a specific 
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input parameter. We assumed a fixed cost of $5 million and a variable cost of $1,000 per 
patient if data on only one parameter (e.g. the treatment efficacy on MCI or AD patients) 
was to be collected. These assumed cost estimates would need to be updated with 
further information.  
Of note, the ENBS of a proposed new study is not the actual benefit of the study 
but the expected benefit prior to conducting the study. Unless the result of a new study 
change the standard of care, the actual benefit to an individual patient is zero. However, 
a new study will always reduce the uncertainty of the decision.31  
 
4.2.2.4 Structural uncertainty  
Many of the structural changes made to the decision model can be thought of in terms of 
missing parameters or parameters assigned a single and often extreme value.13,36 
Considering structural uncertainty by parameterizing allows us to more fully characterize 
the uncertainty in a decision analysis. Accordingly, we presented the CEA result with the 
assumption that treatment effect duration on MCI patients varied between 3 to 10 years 
as defined by an uniform distribution comparing with the constant assumption (3 years) 
in the base case to explore the structural uncertainty. 
 
 
All analyses were performed in TreeAge (version TreeAge Pro 2013, TreeAge Software, 
INC, Williamstown, Mass), Microsoft Excel (Microsoft Corp., Redmond, WA), and R 
software (version 3.0.3; R Foundation for Statistical Computing, Vienna, Austria).  
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4.3 Results 
4.3.1 Cost-effectiveness analysis 
Our CEA results were estimated by 10,000 PSA iterations. CEA results indicated the 
strategies of treat high, and treat high or intermediate were less costly and less effective 
than two strategies with no testing involved. Treating MCI patients at low risk was cost-
effective among all strategies with the highest NHB (2.276 QALYs) (Table 4.2).  
 
4.3.2 Probabilistic sensitivity analysis 
The chance that a strategy is the optimal strategy is the percentage of PSA simulations 
where it has the highest NHB. Figure 4.1 shows that the no MCI treatment strategy was 
optimal in about 37% of the 10,000 iterations of PSA at WTP of $50,000/QALY, whereas 
it was 30% and 21% for treating all MCI patients and treating MCI patients at low risk, 
respectively. Furthermore, strategies of no MCI treatment and treat low were intersecting 
at WTP of $80,000/QALY. Strategies of treat high, and treat high or intermediate showed 
low chances to be cost-effective compared with strategies of no MCI treatment or MCI 
treatment. The chance to be cost-effective was even lower when the WTP threshold was 
higher than $30,000/QALY. 
We further compared MCI treatment and no MCI treatment strategies specifically 
to explore the structural uncertainty. The incremental net health benefit (INHB) between 
strategies of MCI treatment and no MCI treatment was 0.07 QALY (95% credible 
interval, -0.28-0.42) based on the assumption of 3-year treatment effect duration in the 
MCI stage (Figure 4.2). As the treatment effect duration on MCI patients was extended 
(ranged from 3 to 10 years) in the PSA, the expected INHB was reduced to 0.004 (95% 
credible interval: -0.41-0.42) and the chance that the no MCI treatment strategy 
becomes cost-effective also decreased with the treatment effect duration on MCI 
patients varied from 3 to 10 year while held other parameters constant at their mean 
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values; however, the uncertainty surrounding the estimates of INHB increased (a flatter 
distribution, Figure 4.2) as the model extrapolated the duration beyond 3 years. 
 
4.3.3 VOI analysis 
In the following section, we investigated uncertainty surrounding the input parameters in 
the decision model constructed in Paper 2, which examined the cost-effectiveness of all 
six strategies on MCI patients, using a VOI analysis. 
 
4.3.3.1 Total EVPI: overall importance of uncertainty 
We found the total EVPI of $2,122 per patient. This means that after eliminating all the 
potential parameter uncertainty surrounding the decision model, we can expect an 
improvement in NMB of $2,122 per patient. With the annual population that would be 
affected by this decision was estimated at 16 (95% CI, 12-20) thousand patients with 
MCI and the assumption that MCI patients would benefit from this decision for 2 years, 
we found a discounted population to benefit of about 31 (range, 23-39) thousand MCI 
patients. The resulting population EVPI was about $658 million, varied by the amount of 
the affected population ($496-720 million), or an equivalent benefit of 13,152 QALYs 
(assuming a WTP of $50,000 per QALY). 
 
4.3.3.2 Partial EVPI: important parameters 
In our study, 11 out of 42 input parameters either derived from the primary data analysis 
or the published literature had a non-zero partial EVPI. Figure 4.3 shows that treatment 
effectiveness for patients with mild AD was the parameter with the highest partial EVPI 
per patient ($1,300), second was treatment effectiveness for MCI patients ($820), and 
third was the risk of progression to AD for MCI patients at low risk ($480).  
Regardless of the partial EVPI of an individual parameter, we also estimated a 
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set of parameters by categories, including costs in the AD stage, the treatment 
effectiveness, and the risk of progression from MCI to AD, respectively. As Figure 4.4 
shown, parameters in the treatment effectiveness category had the highest informational 
value ($1,946). The overall risk of progression from MCI to AD had the partial EVPI of 
$714, whereas it was $449 for costs in all AD stages. 
 
4.3.3.3 Total and partial EVSI 
We computed the total and partial EVSI for treatment effectiveness for patients with mild 
AD, treatment effectiveness for MCI patients, the risk of progression from MCI to AD and 
a set of cost parameters. Figure 4.5 presents the total EVSI and the partial EVSI of 
parameters as the function of a sample size (n) if a new study is performed. The total 
EVSI was about $2,144 per patient when the sample size was 1,500. Similar to the 
results of the partial EVPI, the parameter of treatment effectiveness for patients with mild 
AD had highest partial EVSI along with the increased sample size and reached the 
plateau approximately when the sample size of a new study was greater than 1,600 (the 
partial EVSI = $1,148), whereas treatment effectiveness for MCI patients, the risk of 
progression from MCI to AD, and the costs in the AD stages reached the maximum 
expected values while the sample sizes were 1,200, 1,100, and 1,400, respectively. It is 
evident that the magnitude of uncertainty (the partial EVPI) is positively related to the 
potential required sample size of a proposed study.  
 
4.3.3.4 ENBS: the optimal sample size 
Hypothetically, a clinical trial collecting data on all parameters (total EVSI) provides a 
framework for calculating the sample size of a new study where the study design and the 
cost information would be provided by the study investigators. For illustrative purposes 
we assumed that a fixed cost of $10 million and a total variable cost of $2,000 per 
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patients for a news study of collecting data on all parameters, whereas it was $5 million 
of a fixed cost and $1,000 of a total variable cost for a single parameter. It was estimated 
about $97 million from a study37 of estimating the average cost that the firm expects to 
spend on the drug when it enters Phase I human clinical trials. We used the estimated 
population, similar to the one in the computation of population EVPI, who would benefit 
of about 31 (range, 23-39) thousand MCI patients. Figure 4.6 presents the study costs, 
the population EVSI, and the ENBS as a function of the sample size (n) of a proposed 
new study. A maximum ENBS of about $56 million, varied by the amount of the affected 
population, was reached for a sample size of about 3,500 MCI patients (the optimal 
sample size) of a hypothetical new study of all input parameters (not shown). The 
population EVSI was about 73 million in this case. Moreover, for the parameter of 
treatment effectiveness for patients with mild AD, the ENBS reached the maximum value 
($ 29 million) at the sample size of 1,700 (Figure 4.6A). The optimal sample size for 
collecting data on treatment effect for MCI patients was $3,000 patients with ENBS of $7 
million (Figure 4.6B).  
The sensitivity analyses for the population to benefit of and the study costs on 
the parameter of treatment effectiveness for patients with mild AD demonstrated that the 
optimal sample size remained robust of 1,700- 2,000 even if the study costs doubled or 
was reduced to half (Table 4.3). 
With the assumption that the duration of the decision problem would affect the 
population for 8 years, the affected population increased from 31 thousand to about 114 
thousand MCI patients but the optimal sample size of a proposed new study of treatment 
effectiveness for patients with mild AD was still around 1,700 patients (not shown).  
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4.4 Discussion 
In this study, we attempt to estimate the societal value of reducing parameter uncertainty 
in the decision whether or not to use CSF biomarker testing to target early treatments for 
patients with MCI given the existing information, and further answer the question 
whether or not more information is required to inform this decision. According to previous 
CEA results, treating MCI patients at low risk was cost-effective compared with no MCI 
treatment, however, there is a possibility that the strategy of no MCI treatment might be 
cost-effective due to uncertainty of the input parameters in our decision model and when 
the PSA results indicated that no MCI treatment might have a higher chance to be cost-
effective than the treat low strategy. There would be a potential opportunity loss if we did 
no consider the strategy of no MCI treatment based on the base case result of CEA. it 
was 37% chance that no MCI treatment would generate greater net benefits than the 
30% of MCI treatment and 21% of the treat low strategy given the existing information at 
WTP of $50,000/QALY. The treatment effect duration on MCI patients had little impact 
here when we modified the model structure by allowing the parameter varied between 3 
to 10 years.  
Due to the inconsistent results on the base-case CEA and PSA, we applied VOI 
analysis to determine whether or not the expected value of reducing uncertainty, through 
more research, of the parameters in our decision model justifies the cost of additional 
research. We found the population EVPI of $658 (range by the affected population, 
$496-$820) million. This indicates that if we could eliminate all uncertainty regarding this 
decision, we would expect a societal financial benefit of about $658 million, which is 
equivalent to a societal health benefit of 13,152 QALYs. The population EVPI for this 
decision measures the maximum possible payoff from a hypothetical research collecting 
data on all parameters for more precise estimates.6 Moreover, it might be feasible to 
compare the expected societal benefit of $658 million with the expected societal benefit 
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of other proposed research projects to set research priorities. The decision uncertainty, 
measured by the population EVPI, regarding whether or not to use CSF biomarker 
testing on patients with MCI to decide the optimal treatment strategy turned out to be 
substantial in contrast to other clinical questions that have been addressed using VOI 
approach.3,6 For example, it was estimated the population EVPI of $339 million in a 
study evaluating whether or not to apply donepezil treatment on AD patients6 (4-years 
effect duration) and $0.5 million of a study to investigate the use magnetic resonance 
imaging on patients with acute knee trauma in an emergency department setting.3 One 
of the possible reasons why the substantial difference of the population EVPI between 
our and their studies may be due to the potential population would be benefit of from the 
decision question is relatively greater in our study. 
Eleven parameters were individually responsible for the decision uncertainty: the 
treatment effectiveness for AD and MCI patients, the risk of progression to AD for MCI 
patients at low risk, costs of formal care and informal care for patients with mild AD living 
in the community, and the probability of transition from community to nursing home for 
patients with mild AD. Among them, the main sources of uncertainty were the treatment 
effectiveness. Collecting data on the other 31 parameters has almost no additional 
benefit.  
A future study in which gathering data on the treatment effectiveness of ChEIs for 
mild AD patients would have an optimal sample size of 1,700 with the expected benefit 
of $29 million based on the estimation that about 10% newly diagnosed MCI patients 
would be affected by this decision question for 2 years. Furthermore, sensitivity analyses 
demonstrated that the result of the estimated optimal sample size remains robust with 
varying the study cost assumption. Additional research collecting information on 
treatment effectiveness of ChEIs for MCI patients would have an optimal sample size of 
3,000. 
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It is known that considerable uncertainty is surrounding the treatment 
effectiveness for delaying the progression from MCI to AD and the progression among 
AD stages and thus many clinical trials are undertaken to obtain the better estimate of 
these parameters. By conducting a VOI analysis, we recognize the societal expected 
benefit of potential treatments on MCI patients to delay the AD progression. We then 
estimated the optimal sample size of a new study by maximizing these expected 
benefits. Methodological and computational challenges are the main reasons why a VOI 
analysis may not widely applied in real-life decision questions. Our study provides an 
example by thoroughly accounting for most relevant uncertainty pertaining to this 
decision problem and then presented the optimal sample size of a new study to collect 
more information before making a decision.  
We acknowledge several limitations in this study. First, our decision model 
synthesizing evidences from various resources, were built based on several 
assumptions derived from the insufficient study results, such as the treatment efficacy 
for patients with mild AD or MCI patient, or treatment effect duration on MCI patients (the 
wide range of 95% CI). We may have overestimated the parameter uncertainty and in 
turn affected the results of VOI analysis. Second, we did not and were unable to account 
for all the potential uncertainty in this decision model, such as the type of model used 
(methodological uncertainty), and the applicability or generalizability of these results to a 
similar decision question. However, our analyses on uncertainty of parameters, structure 
(partially), and decision should have explored the most significant uncertainty that 
commonly appeared on the evaluation of the cost-effectiveness of a particular 
intervention. Finally, we used non-parametric GAM method proposed by Strong et 
al.,30,33 which was introduced in last two years, in this study due to the feasibility and the 
convenience. Further validation studies, especially the computation of the EVSI, will be 
beneficial to determine the applicability of this method in myriad of decision questions. 
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Several methods have also been proposed for conducting a VOI analysis,38,39 however, 
the results of which parameter generated the highest expected value should be 
indifferent even if they produce different value due to the method used. Future research 
of comparing different methods of conducting a VOI analysis may shed a light in the 
application of VOI analysis in a clinical problem.   
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4.5 Conclusion 
Given our estimates of study costs, the efficient study design for the use of CSF 
biomarker testing on MCI patients for targeted early treatment involves a trial of 1,700 
patients on treatment effectiveness for patients with mild AD and a trial of 3,000 patients 
on treatment effectiveness for MCI patients. VOI analysis provides value-based 
information in additional to the typical sensitivity analysis (deterministic or probabilistic) 
to examine the importance of input parameters. Moreover, VOI analysis may add some 
useful reference for policy makers, especially on the prioritization research projects 
based on their hypothetical societal benefit.  
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Table 4.1 Characterization of input parameters for the early identification model. 
Parameter Mean 95% CI Distribution Source 
Annual probability of progression from MCI to AD by CSF biomarker score 27 
  low-risk group 0.064 0.01-0.16 Beta(2.46, 35.93) 
   intermediate-risk group 0.108 0.03-0.22 Beta(4.05, 33.48) 
   high-risk group 0.244 0.17-0.33 Beta(27.89, 86.40) 
 Annual transition probabilitya 
   
24,30 
  Stage to stage (AD) 
        mild to moderate 0.167 0.156-0.178 Beta(690.43, 3443.86) 
     mild to severe 0.014 0.010-0.018 Beta(59.63, 4199.86) 
     moderate to severe 0.299 0.286-0.312 Beta(1355.02, 3176.83) 
   Community to nursing home 
        mild AD 0.012 0-0.028 Beta(2.27, 186.70) 
     moderate AD 0.034 0-0.069 Beta(3.57, 101.46) 
     severe AD 0.066 0.005-0.128 Beta(3.74, 52.91) 
 Excess mortality due to AD  
    (additive effect) 0.11   
  
44,45 
Treatment effectiveness (RR)    
   MCI patients 0.84 0.70-1.00 Lognormal(-0.17, 0.096) 20 
  AD patients   ) 
35 
    mild to moderate 0.58 0.35-0.76 Lognormal(-0.55, 0.198)  
    moderate to severe 0.95 0.64-1.41 Lognormal(-0.05, 0.114)  
Treatment harm    
   Annual prob. of AE (control) 0.23 0.2-0.26 Beta(173.78, 581.77) 38 
  AEs in MCI (RR) 1.09 1.02-0.16 Lognormal(0.086, 0.02) 20 
  AEs in AD (RR) 2.51 2.14-2.95 Lognormal(0.92, 0.08) 37 
  Withdrawal due to AEb 0.19 0.14-0.24 Beta(41.67, 181.76) 37 
  Withdrawal due to non-AE 0.049 0.037-0.063 Beta(52.37, 1016.4) Assumed 
Health utility     
  MCI 0.73 0.58-0.88 Beta(23.86, 8.82) 33,41 
  AD     
    Mild     
      community 0.68 0.54-0.82 Beta(28.34, 13.34)  
      nursing home 0.71 0.57-0.85 Beta (27.97, 11.42)  
    Moderate     
      community 0.54 0.43-0.65 Beta(42.08, 35.85)  
      nursing home 0.48 0.37-0.59 Beta(37.59, 40.72)  
    Severe     
      community 0.37 0.29-0.45 Beta(67.3, 114.6)  
      nursing home 0.31 0.24-0.38 Beta(51.72, 115.11)  
  AEc  0.99 0.988-0.991 Beta(9800, 99) Assumed,43 
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Table 4.1 Continued. 
Parameter Mean 95% CI Distribution Source 
Cost ($, per person-year) 
     MCI 7,744 3,872-11,617 Gamma(15.36, 0.0020) 65 
  Formald 
   
55 
    Mild AD 
          community 9,104 4,552-13,657 Gamma(15.36, 0.0017) 
       nursing home 49,371 24,685-74,056 Gamma(15.37, 3.11) 
     Moderate AD 
          community 13,452 6,726-20,178 Gamma(15.36, 0.0011) 
       nursing home 53,736 26,868-80,604 Gamma(15.37, 2.86) 
     Severe AD 
          community 20,276 10,138-30,414 Gamma(15.37, 7.58) 
       nursing home 57,584 28,792-86,377 Gamma(15.37, 2.67) 
   Informale  
   
55 
    Mild AD 
          community 11,528 5,764-17,291 Gamma(15.36, 0.0013) 
       nursing home 1,229 615-1,844 Gamma(15.32, 0.0125) 
     Moderate AD 
          community 19,955 9,978-29,933 Gamma(15.36, 7.70) 
       nursing home 944 472-1,416 Gamma(15.34, 0.0163) 
     Severe AD 
          community 20,115 10,058-30,173 Gamma(15.37, 7.64) 
       nursing home 998 499-1,497 Gamma(15.32, 0.0153) 
   Drug (donepezil) 2,844 1,422-4,266 Gamma(15.35, 0.0054)) AWP,66 
  Office visit due to   
    treatment (per time) 81 41-122 Gamma(14.88, 0.1837) 
31 
  CSF biomarker testing  
    (per person) 315 158-473 Gamma(15.50, 0.0492) 
67 
aWe obtained the combined stage and nursing home transition probabilities by multiplying stage-to-stage 
and stage-to-nursing home transitions.  
bAnnual probability derived from 6-month data by the exponential function (0.19=1-exp[-0.1032*2]). 
cIncorporated as disutility due to the treatment 
d, eEstimates from published studies. 
Abbreviation: AD, Alzheimer’s disease; MCI, mild cognitive impairment; RR, relative risk; AE, adverse event; 
AWP, average wholesale price; Com, community; NH, nursing home; CI, confidence interval. 
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Table 4.2 Cost-effectiveness results for CSF biomarker testing and treatment on 
patients with MCl.* 
Strategy§ Cost ($) QALYs ICER ($/QALY)¶ 
Treat high or intermediate 265,211 7.487  
Treat high 265,445 7.499 Weakly dominated 
MCI treatment 265,665 7.515 16,500 
No MCI treatment 270,609 7.683 29,400 
Treat low or intermediate 271,460 7.699 Weakly dominated 
Treat low  271,694 7.710 39,500 
*If MCI patients received treatment, no treatment was provided when they convert to AD. 
§MCI treatment stands for treating all MCI patients, treat high was treating MCI patients at high 
risk, treat high or intermediate was treating MCI patients at high or intermediate risk, treat low 
was treating MCI patients at low risk, treat low or intermediate was treating MCI patients at low or 
intermediate risk, and no MCI treatment was no treatment on all MCI patients until they convert to 
AD (based on clinical expert opinion). 
¶The value was rounded to the nearest $100. 
Abbreviation: CSF, cerebrospinal fluid; MCI, mild cognitive impairment; QALYs, quality-adjusted 
life years; ICER, incremental cost-effectiveness ratio. 
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Table 4.3 Estimation of expected net benefit of sampling by the affected population and the study costs on the parameter of 
treatment effectiveness for patients with mild AD. 
Affected population             
(thousand)* 
Study cost 
Mean Lower Upper 
ENBS Optimal n ENBS Optimal n ENBS Optimal n 
 Mean, 30,983  29,318,538 1,700 33,154,395 2,000 22,654,395 2,000 
 Lower, 23,391  20,492,803 1,700 24,172,855 2,000 13,672,855 2,000 
 Upper, 38,626  38,203,905 1,700 42,196,622 2,000 31,696,622 2,000 
*The mean, lower bound and upper bound of the study cost were $5 million, $2.5 million, and $10 million for the fixed cost and $1,000, $500, and 
$2,000 for the varied cost per patient, respectively. 
AD: Alzheimer’s disease; ENBS: Expected net benefit of sampling. ENBS= population expected value of sampling information (EVSI) – study 
costs. 
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Figure 4.1 Cost-effectiveness acceptability curve showing the probability each strategy 
is optimal at various willingness to pay (WTP) thresholds given. The total probability 
adds to 1 for each WTP threshold. 
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Figure 4.2 Comparison of the distributions of incremental net health benefit (INHB) of no 
MCI treatment vs. MCI treatment between treatment effect duration with 3-year and with 
varying from 3 to 10 years on MCI patients. MCI: mild cognitive impairment.
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Figure 4.3 Partial expected value of perfect information (partial EVPI) for an individual parameter. AD: Alzheimer’s disease; MCI; 
mild cognitive impairment; Com: community.  
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Figure 4.4 Partial expected value of perfect information (partial EVPI) for sets of parameters. AD: Alzheimer’s disease; MCI; mild 
cognitive impairment. Treatment effectiveness includes the treatment effect both on MCI patients and on patients with mild AD. 
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Figure 4.5 Partial expected value of sampling information (partial EVSI) by sets of parameters. AD: Alzheimer’s disease; MCI; mild 
cognitive impairment. 
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Figure 4.6 Population expected value of sample information (EVSI) for treatment 
effectiveness for patients with mild AD (Panel A) and treatment effectiveness for MCI 
patients with (Panel B), study costs, and expected net benefit of sampling (ENBS). 
ENBS= population EVSI – study costs. Study costs for an individual parameter are $5 
million of a fixed cost and $1,000 per patient of a variable cost, respectively. 
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Appendix 4.A Schematic diagram of CSF biomarker testing and subsequent treatment on patients with MCI. 
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Appendix 4.B Illustration of expected value of perfection information (EVPI) calculation 
In this simplified example, we modeled the expected value of outcomes (net monetary benefit, NMB) from our decision model based 
on only two strategies - treat all MCI patients (MCI treatment) or treat only when MCI patients convert to AD (no MCI treatment). We 
assumed two parameters of the risk of progression from MCI to AD (mean = 0.1; SD = 0.03) and treatment effectiveness for MCI 
patients (mean = 0.8; SD = 0.12). Both followed a beta distribution in the PSA. The table below represented the simulated output 
from ten iterations generating a NMB for each strategy. With current information (the risk of progression to from MCI AD and the 
treatment effectiveness), the best we can do is to choose the alternative with the highest expected NMB [maxd Eθ NMB(d, θ)], which 
in this example is to choose treating all MCI patients with expected NMB with $393,300 in this example. With perfect information (the 
resolution of uncertainty surrounding these two parameters), we could choose the strategy with the maximum benefit for each 
iteration [maxd NMB(d, θ)], this is, choose MCI treatment for iteration 1; no MCI treatment for iteration 2, no MCI treatment for 
iteration 3, and so on. However, we do not know in advance which of these estimates of input parameters will turn out to be true, so 
the expected NMB with perfect information is simply the expectation of the maximum NMB ($404,800). The EVPI is then the 
difference between the expected NHB with the perfect information and with current information ($404,800 - $393,300 = $11,500). 
This is equal to the average opportunity loss of making a wrong decision in the samples of the PSA output.5 
Table. EVPI calculation algorithm: 10 iterations of second-order Monte Carlo simulation. 
Iteration P(AD) Rx Effect NMB (early Rx) NMB (late Rx) Sample best Sample Max Baseline Max Opportunity loss 
1 0.08 0.57 504,500 426,500 Treat 504,500 504,500 504,500-504,500 = 0 
2 0.04 0.83 549,000 598,000 No treat 598,000 549,000 598,000-549,000 = 49,000 
3 0.15 0.86 275,000 277,500 No treat 277,500 275,000 277,500-275,000 = 2,500 
4 0.13 0.68 318,500 296,000 Treat 318,500 318,500 318,500-318,500 = 0 
5 0.12 0.86 321,500 318,500 Treat 321,500 321,500 321,500-321,500 = 0 
6 0.06 0.90 457,500 504,000 No treat 504,000 457,500 504,000-457,500 = 46,500 
7 0.14 0.69 319,500 287,000 Treat 319,500 319,500 319,500-319,500 = 0 
8 0.08 0.76 410,000 427,000 No treat 427,000 410,000 427,000-410,000 = 17,000 
9 0.09 0.69 459,000 414,500 Treat 459,000 459,000 459,000-459,000 = 0 
10 0.13 0.68 318,500 296,000 Treat 318,500 318,500 318,500-318,500 = 0 
Average 0.10 0.75 393,300 384,500 60% early Rx 404,800 393,300 Overall EVPI = $11,500 
   
maxd Eθ NMB(d, θ) 
  
Eθ maxd NMB(d, 
θ) 
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Note:  
1. Net monetary benefit (NMB)= QALY × λ – cost. λ is willingness to pay and is $50,000/QALY. 
2. Expected value of perfect information (EVPI) = 1
𝑁𝑁
∑ 𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑𝑁𝑁𝑁𝑁𝑁𝑁�𝑑𝑑,𝜃𝜃(𝑛𝑛)�𝑁𝑁𝑛𝑛=1 − 𝑚𝑚𝑚𝑚𝑚𝑚𝑑𝑑 1𝑁𝑁 ∑ 𝑁𝑁𝑁𝑁𝑁𝑁(𝑑𝑑,𝜃𝜃(𝑛𝑛))𝑁𝑁𝑛𝑛=1   = 11,500. 
3. E: expectation; θ: parameters of interest; d: treatment strategies (MCI treatment or no MCI treatment), which was 2 in this example; N: the 
number of iteration, which was 10 in this case; P(AD): the risk of progression from MCI to AD; Rx effect: treatment effectiveness for MCI patients. 
4. Sample best, the strategy with the highest net benefit of the sample; Baseline Max, the outcome of the strategy with the overall optimal 
outcome; Sample Max, the outcome of the strategy with the highest net benefit of the sample; Treat, MCI treatment; No treat, no MCI treatment. 
 
  
 
Chapter 5. Summary and Implications for Research and Policy 
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The objective of my thesis was to explore the potential of using cerebrospinal fluid (CSF) 
biomarker testing to target early treatment for patients with mild cognitive impairment 
(MCI) who are at risk of developing Alzheimer’s disease (AD). 
In paper 1, I examined whether or not CSF biomarker levels allow for risk 
stratification among MCI patients to identify those patients at higher risk of developing 
AD. I analyzed data on MCI patients from the Alzheimer’s Disease Neuroimaging 
Initiative to estimate their risk of developing AD for up to 6 years on the basis of baseline 
CSF biomarkers. I used time-dependent receiver operating characteristic (ROC) analysis 
to identify the best combination of biomarkers to discriminate those who converted to AD 
from those who remained stable. I used these data to construct a multi-biomarker score 
and estimated the risk of progression to AD for each quintile of the multi-biomarker 
score. I found that Aβ1-42 and P-tau181p were the best combination among CSF 
biomarkers to predict the overall risk of developing AD among MCI patients (area under 
ROC curve= 0.77). The hazard ratio of developing AD among MCI patients with high-risk 
biomarker scores (the 3rd, 4th, and 5th quintiles) was about 4 times greater than MCI 
patients with low-risk scores (the 1st quintile) (95% confidence interval [CI], 1.93-7.26). 
The index developed in my thesis constitutes a reasonable measure with regard to the 
risk classification of MCI patients to target early interventions (such as potentially 
effective treatments or life management strategies), however, further validation studies 
should be applied on a population with relatively early stage of MCI to fully describe the 
continuum of CSF biomarker levels and the disease progression of MCI for better 
discriminatory performance if possible. Furthermore, cost-effectiveness of using 
biomarker testing combined with subsequent interventions could be performed to show 
the utility of our risk stratification approach to payers by targeting different intervention 
strategies based on the risk level determined by this index (with accurate diagnosis of 
MCI as the premise).  
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In Paper 2, I quantified the potential clinical value of CSF biomarker testing for 
patients with MCI. I developed a state-transition Markov model to project AD-free life 
years (i.e., average time to conversion to AD), quality-adjusted life years (QALYs), and 
lifetime costs. I conducted a cost-effectiveness analysis (CEA) on the use of CSF 
biomarker testing with cholinesterase inhibitor treatment for MCI patients to delay the 
clinical diagnosis of AD (test-treat) compared to no testing, including treating only when 
MCI patients convert to AD (no MCI treatment), and treating all MCI patients (MCI 
treatment). For the test-treat strategies, we considered treating different levels of risk 
using results from Paper 1- treating MCI patients at high risk or treating MCI patients at 
high or intermediate risk. CEA results indicated that no MCI treatment resulted in the 
highest cost and the highest effectiveness, with an incremental cost-effectiveness ratio 
of $29,400 per QALY compared with MCI treatment. With accounting for uncertainty of 
all input parameters, PSA results showed that there was a 63% chance that no MCI 
treatment was cost-effective over a 37% chance of MCI treatment was preferred. In 
addition, it was shown that the MCI treatment strategy would produce greatest benefits if 
we allowed treatment initiated in both MCI and AD stages. This implied that an 
alternative treatment for patients with mild AD with the relative risk not greater than 0.66 
(less effectiveness) and comparable to the current treatment on MCI patients, which 
allows for the continued treatments, would have the significant impact on the CEA 
results. Accordingly, it is of value to explore the possibility of treatment continuum from 
MCI to AD stages. Although the primary test-treat strategies were never found to be 
cost-effective, we found the strategy of treating MCI patients at low risk was cost-
effective when targeting MCI patients at low risk in the post-hoc analysis. Based on the 
current evidence, this study demonstrates the potential for early-targeted interventions 
for MCI patients who are at risk of developing AD, especially for those at low risk.  
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In Paper 3, I estimated the expected value of reducing parameter uncertainty 
related to the decision whether or not to target early treatments on patients with MCI 
who are at risk of developing AD. Uncertainty surrounding the input parameters of the 
decision model constructed in Paper 2, including all six treatment strategies on MCI 
patients was assessed by value of information analyses (VOI) to estimate the potential 
benefits of gathering more information (through additional research) about the input 
parameters. The total expected value of perfect information (EVPI) of additional research 
of collecting data on all input parameters was $2,122 per patient. The parameter of 
treatment effectiveness for patients with mild AD and treatment effectiveness for MCI 
patients were responsible for most of uncertainty (partial EVPI = $1,300, and $820, 
respectively). For illustrative purpose of how to use EVSI to estimate the optimal size of 
a new study, we demonstrated that new studies, given some assumptions on the study 
costs, in which collecting data on the parameter of treatment effectiveness for patients 
with mild AD would have an optimal sample size of 1,700 patients. A study collecting 
data on the treatment effectiveness for MCI patients would have an optimal sample size 
of 3,000 patients. Methodological and computational challenges are the main reasons 
why VOI analysis may not be widely applied in real-life decision problems. Several 
methods have been proposed for conducting VOI analysis, however, and future research 
of comparing different methods may shed light on how to apply VOI analysis to a clinical 
problem. Our study provided an example by thoroughly accounting for the most relevant 
uncertainty pertaining to a decision and also estimated the optimal size of a new study 
on a specific input parameter if the new study is justified. This would be informative in 
additional to the typical sensitivity analysis (deterministic or probabilistic). Moreover, VOI 
analysis may add some useful reference for policy makers, especially on the 
prioritization research projects based on their hypothetical societal benefit. 
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Overall, CSF biomarkers provide the potential of categorizing MCI patients into different 
risk levels of developing AD for targeted early interventions, although the risk levels of 
progression from MCI to AD was only significant in the high-risk group (not in the 
intermediate-risk group) compared to the low-risk group. Results showed that CSF 
biomarkers seems to add value to guide whether or not to target early treatments on 
MCI patients in a CEA framework, especially for those at low risk. With future additional 
research on the key parameter (treatment effectiveness for MCI patients and treatment 
effectiveness for patients mild AD), however, CEA might produce different results. Our 
model and the findings from our analyses could be used to guide further research 
evaluating the cost-effectiveness of other biomarkers used to target early treatment on 
MCI patients at risk of developing dementia. 
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